[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11762
1. Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, Montalban C, Matutes E, Wotherspoon A, Piris MA: Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica; 2010 Jul;95(7):1122-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.
  • BACKGROUND: Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification.
  • DESIGN AND METHODS: We have retrospectively analyzed the disease features in a highly selected series of 17 patients diagnosed as splenic diffuse red pulp small B-cell lymphoma.
  • Clinical manifestations were mainly derived from splenomegaly.
  • All cases showed a purely diffuse pattern of splenic infiltration by monomorphous small cells with small round nuclei and pale cytoplasm.
  • Peripheral blood cells were small to medium-sized, with clumped chromatin and round nuclear outline and villous cytoplasm.
  • Neoplastic cells had a CD20(+), CD23(-), bcl6(-), Annexin A1- phenotype, with frequent expression of DBA44+ (15/17) and IgG (10/15).
  • FCM data had a B-cell phenotype (CD19(+), CD20(+), CD22(+)) with FMC7 (10/11) and CD11c (5/8) expression.
  • CONCLUSIONS: Our data suggest that splenic diffuse red pulp small B-cell lymphoma is a distinct entity with morphological and immunophenotypical features that differ from those of other splenic lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1999 Nov;23(11):1041-5 [10576509.001]
  • [Cites] Haematologica. 2008 May;93(5):670-9 [18367492.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1299-304 [11830479.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Leukemia. 1987 Apr;1(4):294-8 [3499540.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):211-23 [8554111.001]
  • [Cites] Histopathology. 1996 Dec;29(6):571-5 [8971565.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):438-46 [17325486.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2253-60 [18042795.001]
  • [Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • (PMID = 20220064.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2895036
  •  go-up   go-down


2. Chen X, Lv P, Liu J, Xu K: Apoptosis of human hepatocellular carcinoma cell (HepG2) induced by cardiotoxin III through S-phase arrest. Exp Toxicol Pathol; 2009 Jul;61(4):307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis of human hepatocellular carcinoma cell (HepG2) induced by cardiotoxin III through S-phase arrest.
  • In the present study, we investigated whether CTX III affects cell growth and cell cycle progression of hepatocellular carcinoma cell (HepG2).
  • We found that the proliferation of HepG2 cell was inhibited by CTX III, to some extent, in a time- and dose-dependent manner (IC50 2.58microg/ml at 24h).
  • Flow cytometric analysis and annexin V labeling also demonstrated that CTX III increased the percentage of apoptotic cells being associated with cell cycle arrest at S-phase.
  • Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blot revealed that cyclin D1, cyclin A and cyclin E, which involved in cell apopotosis and cell cycle progression, were down regulated both at transcription and translation levels.
  • CTX III-induced caspase-8, -9 and caspase-3 activation, generation of truncated Bid, releasing of cytochrome c and the change of Bcl-2/Bax ratio on protein and mRNA levels.
  • These findings demonstrated that cyclin D1, cyclin B and cyclin A down-regulation, change of Bcl-2/Bax ratio and caspase-8 and -9 activation contribute to CTX III-induced HepG2 cell apoptosis.
  • [MeSH-minor] Blotting, Western. Caspases / metabolism. Cell Culture Techniques. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Cytochromes c / metabolism. Flow Cytometry. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986802.001).
  • [ISSN] 1618-1433
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobra Cardiotoxin Proteins; 0 / cardiotoxin III, Naja naja atra; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspases
  •  go-up   go-down


3. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S: MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood; 2007 May 1;109(9):4006-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
  • Interactions between MEK1/2 inhibitors and the dual Abl/Src kinase inhibitor dasatinib (BMS-354825) were examined in chronic myeloid leukemia (CML) cell lines and primary specimens.
  • Cotreatment of K562 or LAMA cells with subtoxic or marginally toxic concentrations of PD184352 (or U0126) and dasatinib synergistically potentiated mitochondrial damage, caspase activation, and apoptosis.
  • Similar interactions were observed in CD34(+) cells from one CML patient-derived but not in a normal human CD34(+) bone marrow cell specimen.
  • These interactions were associated with multiple perturbations in survival signaling pathways, including inactivation of Bcr/Abl, STAT5, and ERK1/2; down-regulation of Bcl-x(L) and Mcl-1; and dephosphorylation/activation of Bim.
  • Bim knockdown by shRNA suppressed BAX and BAK conformational change and protected cells from dasatinib/PD184352 lethality.
  • Conversely, K562 cells ectopically expressing Mcl-1 or Bcl-x(L) were significantly less susceptible to dasatinib/PD184352 toxicity.
  • Notably, the dasatinib/PD184352 regimen was active against leukemic cells exhibiting various forms of imatinib mesylate resistance, including Bcr/Abl overexpression, Lyn activation, and several Bcr/Abl kinase domain mutations (eg, E255K, M351T), but not T315I.
  • Together, these findings suggest that strategies combining dasatanib with MEK1/2 inhibitors warrant further investigation in Bcr/Abl(+) malignancies, particularly in the setting of imatinib mesylate-resistant disease.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Ann Med. 2006;38(3):200-11 [16720434.001]
  • [Cites] FEBS Lett. 2006 Jun 12;580(14):3539-44 [16730715.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5126-35 [12941844.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16 [14613031.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:132-52 [14633780.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):283-8 [14735164.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):672-7 [14744784.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(14):6172-83 [15226421.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7117-26 [15466208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15313-7 [15486085.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):23255-61 [8798523.001]
  • [Cites] Cell. 1996 Nov 15;87(4):619-28 [8929531.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):180-6 [9069255.001]
  • [Cites] EMBO J. 1997 May 1;16(9):2384-96 [9171352.001]
  • [Cites] Nature. 1998 Jan 29;391(6666):496-9 [9461218.001]
  • [Cites] Genes Dev. 1998 Apr 1;12(7):968-81 [9531535.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] Mol Cell. 1999 Apr;3(4):413-22 [10230394.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400 [15705718.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3303-11 [15626746.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1659-69 [15747376.001]
  • [Cites] Blood. 2005 May 15;105(10):4021-7 [15665113.001]
  • [Cites] Genes Dev. 2005 Jun 1;19(11):1294-305 [15901672.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2332-8 [16772610.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1068-71 [12130526.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2976-84 [12231544.001]
  • [Cites] Science. 1999 Nov 12;286(5443):1358-62 [10558990.001]
  • [Cites] Blood. 2000 Aug 1;96(3):925-32 [10910906.001]
  • [Cites] J Cell Biochem. 2000 Sep 7;79(3):355-69 [10972974.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2269-76 [10979976.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3343-56 [11071626.001]
  • [Cites] Curr Opin Oncol. 2000 Nov;12(6):543-9 [11085453.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2449-76 [11749383.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):188-99 [11782377.001]
  • [Cites] Blood. 2002 May 1;99(9):3472-5 [11964322.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8804-16 [12483533.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7149-53 [12499247.001]
  • [Cites] Blood. 2003 Jan 15;101(2):690-8 [12509383.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5367-76 [12454021.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Mol Cancer Ther. 2003 Mar;2(3):219-24 [12657715.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2118-26 [12727828.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4667-79 [12623839.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):24205-11 [15845549.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Curr Opin Pharmacol. 2005 Aug;5(4):350-6 [15955734.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5281-93 [16009947.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2648-55 [16200198.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93 [16203792.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9369-82 [16227588.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9436-44 [16230407.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1007-14 [16424036.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47 [16609040.001]
  • (PMID = 17218385.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088906; United States / NCI NIH HHS / CA / CA 88906; United States / NCI NIH HHS / CA / P01 CA072955; United States / NCI NIH HHS / CA / CA 72955; United States / NCI NIH HHS / CA / R01 CA100866; United States / NCI NIH HHS / CA / R01 CA063753; United States / NCI NIH HHS / CA / R01 CA093738; United States / NCI NIH HHS / CA / CA 63753; United States / NCI NIH HHS / CA / CA 100866; United States / NCI NIH HHS / CA / CA 93738
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 0 / Benzamides; 0 / Butadienes; 0 / Nitriles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 0 / U 0126; 8A1O1M485B / Imatinib Mesylate; EC 2.7.1.- / MAP2K2 protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / src-Family Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP Kinase Kinase 2; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ PMC1874569
  •  go-up   go-down


Advertisement
4. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC: Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther; 2005 Aug;4(8):1277-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria.
  • Pristimerin, a naturally occurring triterpenoid, has been shown to cause cytotoxicity in several cancer cell lines.
  • In the present study, human breast cancer MDA-MB-231 cells treated with pristimerin (1 and 3 micromol/L) showed rapid induction of apoptosis, as indicated by caspase activation, DNA fragmentation, and morphologic changes.
  • Treatment of tumor cells with pristimerin resulted in a rapid release of cytochrome c from mitochondria, which preceded caspase activation and the decrease of mitochondrial membrane potential.
  • Pristimerin did not significantly alter the protein level of Bcl-2 family members (Bcl-2, Bcl-X(L), and Bax), nor did it induce Bax translocation.
  • Moreover, Bcl-2 overexpression fails to prevent pristimerin-induced apoptosis.
  • The generation of reactive oxygen species in MDA-MB-231 cells was also not affected by pristimerin.
  • In a cell-free system, pristimerin induced cytochrome c release from isolated mitochondria.
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Caspase Inhibitors. Cytochromes c / metabolism. Female. Humans. Intracellular Membranes / drug effects. Intracellular Membranes / metabolism. Membrane Potentials / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reactive Oxygen Species / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093444.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Antineoplastic Agents; 0 / Caspase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 0 / Triterpenes; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 1258-84-0 / pristimerin; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspases
  •  go-up   go-down


5. Kondo N, Furuya H, Yamamoto S, Nakano A, Sakashita Y: Diffuse large B-cell lymphoma in the ampulla of vater causing obstructive jaundice: report of a case. Surg Today; 2008;38(1):76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in the ampulla of vater causing obstructive jaundice: report of a case.
  • We report a case of diffuse large B-cell lymphoma (DLBCL) in the ampulla of Vater, causing painless obstructive jaundice in a 78-year-old woman.
  • We performed pylorus-preserving pancreatoduodenectomy to establish a histological diagnosis, relieve the obstructive jaundice, and remove the narrowed second portion of the duodenum.
  • Histological and immunohistochemical examination of the surgically resected specimen confirmed a diagnosis of DLBCL.
  • Chemotherapy is the mainstay of treatment for DLBCL; however, surgery still plays an important role when the histological diagnosis cannot be established preoperatively and when complications are not amenable to nonsurgical therapy.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / complications. Jaundice, Obstructive / etiology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Aged. Cholangiography. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Pancreaticoduodenectomy / methods

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1987 Jun;5(6):969-81 [3295131.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2083-6 [7512441.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3083-8 [12115338.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Surgery. 2003 Sep;134(3):496-500 [14555939.001]
  • [Cites] J Comput Tomogr. 1986 Jan;10 (1):89-92 [3943363.001]
  • [Cites] South Med J. 1995 May;88(5):583-5 [7732453.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3186-9 [11721770.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1543-6 [9317083.001]
  • (PMID = 18085371.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Kalia S, Bansal MP: Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2. J Biochem Mol Toxicol; 2008 Nov-Dec;22(6):371-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2.
  • Testicular germ cell apoptosis is normally a continuous process throughout life.
  • However, massive testicular germ cell loss is known to result from a wide variety of cellular stresses including toxicant exposure.
  • Thus, the present study was aimed to investigate the mechanisms of germ cell loss under stress conditions following diethyl maleate (DEM) exposure.
  • The germ cell apoptosis was found to be increased as assessed by terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP biotin nick end labeling (TUNEL) staining, evaluation of histoarchitechture of testis, and germ cell numbers.
  • It was found that the germ cell number was significantly reduced in DEM-treated sections.
  • RT-PCR was carried out to assess Bax/Bcl-2 mRNA expression levels.
  • Immunohistochemistry of Bax and Bcl-2 revealed Bax activation.
  • The prevalence and cellular localization of the above markers in testicular tissues of DEM-treated animals suggest the possible involvement of Bax/Bcl-2 in the male germ cell apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Maleates / toxicity. Oxidative Stress / drug effects. Spermatozoa / cytology. Spermatozoa / drug effects. Testis / cytology. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Animals. Cell Shape / drug effects. Gene Expression Regulation / drug effects. Immunohistochemistry. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 19110998.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Maleates; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; G81WQB56OL / diethyl maleate
  •  go-up   go-down


7. Carmagnat M, Drénou B, Chahal H, Lord JM, Charron D, Estaquier J, Mooney NA: Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma. Oncogene; 2006 Mar 23;25(13):1914-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma.
  • Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigen-presenting cells and B lymphoproliferations.
  • Characteristics of the apoptosis include rapidity and selectivity for mature cells.
  • Follicular lymphomas are particularly refractory to apoptosis.
  • The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement.
  • However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury.
  • Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.
  • [MeSH-major] Apoptosis. Caspase Inhibitors. Caspases / metabolism. HLA-DR Antigens / physiology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301998.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Caspase Inhibitors; 0 / HLA-DR Antigens; EC 3.4.22.- / Caspases
  •  go-up   go-down


8. Zain J, O'Connor OA: Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs; 2010 Dec;28 Suppl 1:S58-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
  • HDAC inhibitors (HDACI) are now emerging as one of the most promising new classes of drugs for the treatment of select forms of non-Hodgkin's lymphoma (NHL).
  • They are particularly active in T-cell lymphomas, possibly hodgkin's lymphoma and indolent B cell lymphomas.
  • Presently, two of these agents, vorinostat and romidepsin, have been approved in the US for the treatment of relapsed and refractory cutaneous T cell lymphomas (CTCL).
  • Gene expression profiles and functional genetic analysis has led to further understanding of the various molecular pathways that are affected by these agents including cell cycle regulation, pathways of cellular proliferation, apoptosis and angiogenesis all important in lymphomagenesis.
  • There is also increasing data to support the effects of these agents on T cell receptor and immune function which may explain the high level of activity of these agents in T cell lymphomas and hodgkin's lymphoma.
  • There is ample evidence of epigenetic dysregulation in lymphomas which may underlie the mechanisms of action of these agents but how these agents work is still not clear.
  • At present several of these HDAC inhibitors are in clinical trials both as single agents and in combination with chemotherapy or other biological agents.
  • Different dosing levels and schedules and the use of isospecific HDAC inhibitors are some of the strategies that are being employed to increase the therapeutic effect of these agents in the treatment of lymphomas.
  • There may also be class differences that translate into specific activity against different lymphoma.
  • HDAC inhibitors will likely be incorporated into combinations of targeted therapies both in the upfront and relapsed setting for lymphomas.
  • [MeSH-major] Histone Deacetylase Inhibitors / therapeutic use. Histone Deacetylases / metabolism. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / enzymology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2009 Aug 8;280(2):192-200 [19345475.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3918-26 [19509169.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3958-69 [19509172.001]
  • [Cites] Br J Haematol. 2009 Sep;146(6):656-9 [19604235.001]
  • [Cites] Br J Haematol. 2009 Oct;147(1):97-101 [19663825.001]
  • [Cites] Br J Haematol. 2009 Nov;147(4):515-25 [19775297.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5459-68 [19826124.001]
  • [Cites] Mol Cell Biol. 2009 Dec;29(23):6149-69 [19805519.001]
  • [Cites] Oncogene. 2010 Jan 14;29(2):157-73 [19855430.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34940-7 [10574969.001]
  • [Cites] EMBO J. 2000 Feb 15;19(4):662-71 [10675335.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1565-72 [10793068.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):642-5 [11034214.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):242-7 [11224524.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3997-4003 [16818698.001]
  • [Cites] BMC Cancer. 2006;6:213 [16928273.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7039-45 [17145826.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jan;6(1):21-2 [17269160.001]
  • [Cites] Nat Med. 2007 Mar;13(3):324-31 [17322895.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2318-22 [17438089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6 [17470784.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1216-8 [17577787.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1773-82 [17525724.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3362-71 [17664484.001]
  • [Cites] Eur J Pharmacol. 2007 Oct 1;571(2-3):88-96 [17628529.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2667-73 [17606765.001]
  • [Cites] Drugs Today (Barc). 2007 Sep;43(9):585-99 [17940636.001]
  • [Cites] Mini Rev Med Chem. 2007 Oct;7(10):1062-9 [17979809.001]
  • [Cites] Eur J Haematol. 2008 Feb;80(2):133-42 [18005386.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):549-58 [18223231.001]
  • [Cites] Mol Cell Biol. 2008 Mar;28(5):1688-701 [18180281.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1148-59 [18337604.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):759-68 [18413790.001]
  • [Cites] Ann Oncol. 2008 May;19(5):964-9 [18296419.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1066-79 [18483296.001]
  • [Cites] Mol Genet Metab. 2008 Jul;94(3):283-6 [18472289.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] Blood. 2008 Aug 15;112(4):981-9 [18495956.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1424-33 [18541724.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):554-65 [20068080.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):256-67 [19874311.001]
  • [Cites] Drugs Today (Barc). 2009 Nov;45(11):787-95 [20126671.001]
  • [Cites] Cancer Sci. 2010 Jan;101(1):196-200 [19817748.001]
  • [Cites] J Hematol Oncol. 2010;3:5 [20132536.001]
  • [Cites] Haematologica. 2010 Apr;95(4):613-21 [20133897.001]
  • [Cites] Med Lett Drugs Ther. 2010 May 31;52(1339):42-3 [20508581.001]
  • [Cites] Blood. 2010 Jun 3;115(22):4478-87 [20233973.001]
  • [Cites] Int J Cancer. 2010 Nov 1;127(9):2199-208 [20127862.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4460-71 [12907619.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):894-901 [14632210.001]
  • [Cites] Cell. 2004 Jan 23;116(2):259-72 [14744436.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6 [14734806.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):627-38 [15023334.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2580-9 [15059915.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1978-88 [15128898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5036-40 [1711217.001]
  • [Cites] Cell. 1994 Jan 28;76(2):263-74 [8293463.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3124-34 [8605326.001]
  • [Cites] Gene Expr. 1996;5(4-5):245-53 [8723390.001]
  • [Cites] Jpn J Cancer Res. 1996 Jul;87(7):751-6 [8698626.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Histopathology. 2008 Sep;53(3):267-77 [18671804.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):92-100 [19011628.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):476-87 [19136931.001]
  • [Cites] Nat Med. 2001 Apr;7(4):437-43 [11283670.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1653-7 [11533489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 [11535817.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] J Invest Dermatol. 2002 Mar;118(3):493-9 [11874489.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2672-81 [12032080.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1203-10 [12152987.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):15-9 [12353228.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5902-5 [12384555.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):127-40 [12406558.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] Cell. 2002 Nov 27;111(5):709-20 [12464182.001]
  • [Cites] Genes Cells. 2002 Dec;7(12):1191-204 [12485160.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):151-63 [12589032.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2914-23 [12515714.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):70-7 [12823347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7818-23 [12810945.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3370-4 [9269998.001]
  • [Cites] Cell. 1997 Aug 22;90(4):595-606 [9288740.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Exp Med. 1999 Jun 21;189(12):1939-46 [10377189.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):273-9 [10381378.001]
  • [Cites] Cell Mol Life Sci. 1999 Jul;55(8-9):1113-28 [10442092.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10826-34 [15572685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5 [15596714.001]
  • [Cites] Nat Med. 2005 Jan;11(1):77-84 [15619633.001]
  • [Cites] Science. 2005 Jan 14;307(5707):269-73 [15653507.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1215-27 [15684376.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702 [15738394.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Mol Cell. 2005 May 27;18(5):601-7 [15916966.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4553-60 [15728122.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3912-22 [15851766.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3971-93 [15897549.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3886-96 [15897551.001]
  • [Cites] Semin Oncol. 2005 Oct;32(5):479-87 [16210089.001]
  • [Cites] Cell Death Differ. 2006 Jan;13(1):129-40 [15947789.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):166-73 [16330674.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3871-4 [16818679.001]
  • (PMID = 21132350.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC3003796
  •  go-up   go-down


9. Hannigan A, Wilson JB: Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol Cancer; 2010 Jul 09;9:184
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In so doing it leads to deregulated cell growth intrinsic to the cancer cell as well as having extrinsic affects upon the tumour microenvironment.
  • These properties and that it is a foreign antigen, lead to the proposition that LMP1 may be a good therapeutic target in the treatment of EBV associated disease.
  • LMP1 is expressed in several EBV-associated malignancies, notably in Hodgkin's lymphoma and nasopharyngeal carcinoma (NPC).
  • RESULTS: In order to explore if LMP1 has a continuous function in established tumours, its activity was inhibited through expression of a dominant negative LMP1 mutant in tumour cell lines derived from transgenic mice.
  • LMP1 is the tumour predisposing oncogene in two different series of transgenic mice which separately give rise to either B-cell lymphomas or carcinomas.
  • Inhibition of LMP1 activity in the carcinoma cell lines lead to a reduction in clonagenicity and clone viability in all of the cell lines tested, even those with low or below detection levels of LMP1.
  • Inhibition of LMP1 activity in the transgenic B-cell lines was incompatible with growth and survival of the cells and no clones expressing the dominant negative LMP1 mutant could be established.
  • CONCLUSIONS: LMP1 continues to provide a tumour cell growth function in cell lines established from LMP1 transgenic mouse tumours, of both B-cell and epithelial cell origin.
  • LMP1 can perform this function, even when expressed at such low levels as to be undetectable, whereby evidence of its expression can only be inferred by its inhibition being detrimental to the growth of the cell.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 [18287029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 [17911266.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73 [11313005.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6730-8 [11559544.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1209-18 [12807717.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] J Virol Methods. 2004 Mar 1;116(1):79-88 [14715310.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] J Virol. 1985 Sep;55(3):710-20 [2991591.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1315-27 [1694724.001]
  • [Cites] J Virol. 1991 Oct;65(10):5558-63 [1680199.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):680-7 [1370649.001]
  • [Cites] J Virol. 1995 Jul;69(7):4390-8 [7769701.001]
  • [Cites] EMBO J. 1996 Jun 17;15(12):3117-26 [8670812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8826-35 [16204053.001]
  • [Cites] Cell Cycle. 2007 Jun 1;6(11):1379-85 [17507800.001]
  • [Cites] Carcinogenesis. 2007 Aug;28(8):1839-48 [17361012.001]
  • [Cites] J Gen Virol. 2008 Nov;89(Pt 11):2821-32 [18931080.001]
  • (PMID = 20618963.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 069113/Z/02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2913984
  •  go-up   go-down


10. Aebischer T, Meyer TF, Andersen LP: Inflammation, immunity, and vaccines for Helicobacter. Helicobacter; 2010 Sep;15 Suppl 1:21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori represents the major etiologic agent of gastritis, gastric, and duodenal ulcer disease and can cause gastric cancer and mucosa-associated lymphoid tissue B-cell lymphoma.
  • The hope is that by deciphering the deterministic rules--if any--of this interplay, we will eventually be able to predict, treat, and ultimately prevent disease.
  • Induction of effective cell-mediated immunity will be key for the development of a vaccine, and new work published analyzed the relevance and contribution of CD4 T helper cell subsets to the immune reaction.
  • Th17 cells, which are also induced during natural infection, were shown to be particularly important for vaccination.
  • [MeSH-minor] CD4-Positive T-Lymphocytes / immunology. Humans. Th17 Cells / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21054649.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Vaccines
  •  go-up   go-down


11. Sato K, Ozaki K, Fujiwara S, Oh I, Matsuyama T, Ohmine K, Suzuki T, Mori M, Nagai T, Muroi K, Ozawa K: Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma. Int J Hematol; 2010 Nov;92(4):647-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma.
  • According to the international working group response criteria for malignant lymphoma revised in 2007, 18F-fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET) combined with or without computed tomography (CT) is recommended for pre-treatment staging and response assessment among patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
  • Discussed in the present report are patients with malignant lymphoma and second primary carcinomas that were incidentally found by PET/CT.
  • A total of 497 consecutive PET/CT were performed on 290 patients with malignant lymphoma in our institution from April 2008 through March 2010.
  • Two cases were diagnosed at the initial staging, and the others were detected after treatment for lymphoma.
  • The present study suggests that incidental findings by PET in malignant lymphoma can lead to early detection and successful treatment of second malignancies.
  • [MeSH-major] Carcinoma / diagnostic imaging. Incidental Findings. Lymphoma. Neoplasms, Second Primary / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Radiology. 2004 Feb;230(2):417-22 [14699176.001]
  • [Cites] Radiology. 1998 Mar;206(3):755-60 [9494497.001]
  • [Cites] Blood. 2007 Nov 15;110(10 ):3507-16 [17709603.001]
  • [Cites] Surgery. 2009 Aug;146(2):274-81 [19628085.001]
  • [Cites] J Nucl Med Technol. 2005 Sep;33(3):145-55; quiz 162-3 [16145222.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):117-24 [17133406.001]
  • [Cites] J Nucl Med. 2005 May;46(5):752-7 [15872346.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12 ):1607-11 [11104553.001]
  • (PMID = 20976633.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Dales JP, Harket A, Bagnères D, Andrac-Meyer L, Xerri L, Frances Y, Taranger-Charpin C: [Plasmablastic lymphoma in a patient with HIV infection: an unusual case located in the skin]. Ann Pathol; 2005 Feb;25(1):45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasmablastic lymphoma in a patient with HIV infection: an unusual case located in the skin].
  • [Transliterated title] Lymphome plasmoblastique du sujet infecté par le VIH: a propos d'un cas très inhabituel de localisation cutanée.
  • We report the case of a plasmablastic lymphoma involving the skin in a 45 year-old HIV-positive patient.
  • Plasmablastic lymphoma was first described in 1997 and is considered to be a diffuse large B-cell lymphoma with a unique immunophenotype and a predilection for the oral cavity.
  • A skin biopsy led to the diagnosis of plasmablastic lymphoma in view of the presence of a dense nodular infiltrate invading the dermis and subcutaneous fat composed of large cells that expressed neither the leucocyte common antigen nor the B- and T-cell antigens CD20 and CD3, but which showed a strong immunostaining with plasma cell marker VS38c.
  • Most of the cells expressed Kappa light chain of immunoglobulins, they did not express Lambda light chain.
  • In situ hybridization with EBER probe revealed detection of Epstein Barr virus in about 15 % of tumor cells.
  • The clinical course was aggressive and rapidly fatal.
  • HIV-associated plasmablastic lymphoma is a poor prognosis malignancy that may resist typing due to the lack of expression of commonly used lymphoid markers.
  • [MeSH-major] HIV Seropositivity / complications. Lymphoma, AIDS-Related / diagnosis. Plasma Cells. Skin Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Humans. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981931.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Sabah M, Cummins R, Leader M, Kay E: Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
  • Tumor growth depends on 2 distinctive pathways: cell proliferation and apoptosis.
  • The p53 pathway is an important regulator of the cell cycle as it triggers growth arrest or leads to apoptosis in response to cellular stress and therefore is commonly targeted during tumorigenesis.
  • Apoptosis is also controlled by the Bcl-2 family, which includes proapoptotic and antiapoptotic proteins.
  • Immunohistochemical stains for p21(WAF1/CIP1), p53, Mdm2, Bcl-2, and Bax proteins were carried out on tissue microarrays.
  • Expression of Bax protein was a common finding in soft tissue sarcoma cases.
  • Bcl-2 was identified in 59 tumors (38.8%) and was more prevalent in high-grade sarcomas (low grade, 25.9%; intermediate grade, 32.5%; high grade, 55.2%).
  • The expression of p53, p21(WAF1/CIP1), and Bcl-2 is closely associated with the histologic grade of the tumor, and therefore these proteins may be used as prognostic markers.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536310.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


14. Wessely MA, Kettner N, Pierre-Jerome C: Postlymphoproliferative disorder affecting bone after a renal transplantation. J Manipulative Physiol Ther; 2005 Jan;28(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postlymphoproliferative disorder affecting bone after a renal transplantation.
  • OBJECTIVE: To illustrate a posttransplant lymphoproliferative lymphoma presenting as a solitary osseous lesion situated in the rib.
  • CLINICAL FEATURES: A 53-year-old man was referred to a surgical department because of persistent local pain over the lower part of his left posterior hemithorax.
  • The histological study of the surgically removed tissue revealed diffuse infiltration of the marrow by lymphoid-like cells.
  • There was evidence of interstitial fibrosis, and further immunohistochemical examination showed the presence of B cells in the specimen confirming the diagnosis of B-cell lymphoma.
  • CONCLUSION: This case report discusses an unusual presentation of a lymphoma induced by immunosuppressive therapy in a patient who had received an organ transplant.
  • [MeSH-major] Bone Neoplasms / etiology. Immunosuppression / adverse effects. Kidney Transplantation. Lymphoma, B-Cell / etiology. Ribs

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726037.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kojima M, Nakamura N, Shimizu K, Tamaki Y, Itoh H, Nakamura S: Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens. Int J Surg Pathol; 2008 Apr;16(2):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens.
  • Two subtypes of marginal zone B-cell lymphoma (eg, mucosa-associated lymphoid tissue [MALT] type and splenic type) have been reported in the lymph node.
  • To determine the presence or absence of marginal zone B-cell lymphoma of MALT type and the splenic type among Waldeyer's ring (WR) lymphomas, 16 tonsillectomy specimens were studied.
  • Ten cases (63%) were marginal zone B-cell lymphoma.
  • Among marginal zone B-cell lymphoma, 7 were the MALT type and the remaining 3 cases of marginal zone B-cell lymphoma were the splenic type.
  • Moreover, 4 cases of 7 MALT-type lymphomas contained numerous large cells (diffuse large B-cell lymphoma arising from a low-grade marginal zone B-cell lymphoma of MALT type).
  • The low incidence of primary mucosa-associated lymphoid tissue type lymphoma of WR in previous reports may be because it is difficult to correctly identify the characteristic histologic findings of MALT-type lymphoma because of the small biopsy size.
  • [MeSH-major] Lymphoid Tissue / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Tonsillar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417673.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Park J, Kim M, Na G, Jeon I, Kwon YK, Kim JH, Youn H, Koo Y: Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens. Mol Cell Endocrinol; 2007 Nov 15;278(1-2):7-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens.
  • In this study, we found that the expression of FKBP51 mRNA in 12 organs of Newcastle disease virus (NDV)-infected chickens was robustly induced.
  • The level of corticosterone in NDV-infected chickens was also elevated, approximately 2- to 6.5-fold in the organs compared to non-infected control chickens.
  • In chicken UMNSAH/DF-1 cells, nuclear factor kappaB (NF-kappaB) was activated in an FKBP51-dependent manner.
  • Regulation of the three NF-kappaB-dependent, anti-apoptotic genes, bcl-2, bcl-x and bfl-1/A1 was investigated in UMNSAH/DF-1 cells.
  • Dexamethasone treatment of UMNSAH/DF-1 cells resulted in up-regulation of bcl-2, and down-regulation of bcl-x and bfl-1/A1.
  • Expression of FKBP51 also resulted in down-regulation of bfl-1/A1, but had no effect on bcl-2 and bcl-x, suggesting the involvement of glucocorticoid-FKBP51-NF-kappaB signaling in the regulation of expression of bfl-1/A1 in UMNSAH/DF-1 cells.
  • We observed organ-specific up- or down-regulation of expression of, bcl-2, bcl-x and bfl-1/A1 in NDV-infected and dexamethasone-treated chickens.
  • Differential regulation of bfl-1/A1, bcl-2 and bcl-x upon NDV-infection and dexamethasone treatment suggests that additional factors are involved in the regulation of these genes.
  • [MeSH-major] Chickens / virology. Gene Expression Regulation. Glucocorticoids / metabolism. NF-kappa B / metabolism. Newcastle disease virus. Tacrolimus Binding Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / genetics. Cell Line. Corticosterone / analysis. Corticosterone / metabolism. Dexamethasone / metabolism. Dexamethasone / pharmacology. Gene Expression / drug effects. HSP90 Heat-Shock Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Tissue Distribution. bcl-X Protein / genetics

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17870233.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BCL2-related protein A1; 0 / Glucocorticoids; 0 / HSP90 Heat-Shock Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 7S5I7G3JQL / Dexamethasone; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / tacrolimus binding protein 5; W980KJ009P / Corticosterone
  •  go-up   go-down


17. Martinez AE, Lin L, Dunphy CH: Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. Arch Pathol Lab Med; 2007 Jul;131(7):1084-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry.
  • CONTEXT: Follicular lymphoma (FL) grading is based on the average number of large transformed cells in 10 neoplastic follicles at x40 high-power field (x10-40 high-power field) examination (grade 1, 0-5 centroblasts per high-power field; grade 2, 6-15 centroblasts per high-power field; grade 3, >15 centroblasts per high-power field).
  • DESIGN: Forty-three FLs initially graded by World Health Organization criteria (grade 1, 12; grade 2, 18; grade 3, 13) were reviewed and stained with CD3, CD20, Ki-67, CD30, CD68, PAX-5, and BCL-6.
  • Retrospective review was performed for the average number of large cells, of large lymphoid cells, of large cells staining with CD3, CD20, BCL-6 (40 cases), and PAX-5, and of all cells staining with CD68, Ki-67, and CD30.
  • CD3 and CD30 stained only 0 to 3 large cells and 0 to 3 cells, respectively, in neoplastic follicles.
  • CD68+ cells represented the large nonlymphoid cells.
  • Increasing FL grades demonstrated increases in Ki-67+ cells.
  • The original grade showed substantial agreement with CD20 and moderate agreement with PAX-5 and BCL-6.
  • The original histologic grade agreed with immunohistochemical-based grade using 2 or more antibodies in 5 of 8 discordant cases (4 by CD20 or BCL-6 and PAX-5; 1 by CD20, PAX-5, and BCL-6).
  • Immunohistochemical stains (ie, CD20, PAX-5, and BCL-6) may more reliably determine the number of large transformed cells in neoplastic follicles; Ki-67 staining correlates with higher FL grades.
  • Immunohistochemical stains may be evaluated in clinical trials of FL patients to determine prognostic significance.
  • [MeSH-major] Lymphoma, Follicular / pathology
  • [MeSH-minor] Antigens, CD. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD30 / analysis. Antigens, Differentiation, Myelomonocytic. B-Cell-Specific Activator Protein / analysis. DNA-Binding Proteins / analysis. Humans. Immunohistochemistry. Ki-67 Antigen / analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616995.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, Differentiation, Myelomonocytic; 0 / B-Cell-Specific Activator Protein; 0 / BCL6 protein, human; 0 / CD68 antigen, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / PAX5 protein, human
  •  go-up   go-down


18. Meredith RF, Knox SJ: Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
  • Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT).
  • Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy.
  • Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979433.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 45
  •  go-up   go-down


19. Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR: Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther; 2007 Feb;6(2):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma.
  • Mesothelioma is a neoplasm of the pleura that is currently incurable by conventional therapies.
  • Previously, we demonstrated that mesothelioma overexpresses BCL-X(L), an anti-apoptotic member of the BCL-2 family.
  • In addition, we have shown that down regulation of BCL-X(L) using a BCL-X(L) antisense oligonucleotide engenders mesothelioma apoptotic cell death in vitro and in vivo.
  • The purpose of this study is to evaluate the efficacy of bcl2/bcl-x(L) inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo.
  • Several bcl-x(L) high-expression tumor cell lines and one normal human cell line were exposed to 2-methoxy antimycin A3.
  • 2-methoxy antimycin A3 demonstrated significant growth inhibition only in these tumor cell lines, with little effect on normal human cells.
  • Treatment with 2-methoxy antimycin A3 alone resulted in a dramatic increase in the induction of apoptosis in the cancer cells.
  • Notably, treatment with 2-methoxy antimycin A3 does not alter BCL-2 family protein expression.
  • Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/x(L) inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma.
  • [MeSH-major] Antimycin A / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Genes, bcl-2 / drug effects. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. bcl-X Protein / drug effects
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Humans. In Vitro Techniques

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2007 Mar;6(3):465-6 [17471026.001]
  • (PMID = 17224645.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; 642-15-9 / Antimycin A
  •  go-up   go-down


20. Pilka R, Mícková I, Lubuský M, Dusková M, Rícánková M, Kudela M: [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer]. Ceska Gynekol; 2008 Jul;73(4):222-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
  • [Transliterated title] Exprese p53, Ki-67, bcl-2, c-erb-2, estrogenového, a progesteronového receptoru v endometriálním karcinomu.
  • OBJECTIVE: To assess the immunohistochemical expression of p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors in endometrial cancer patients.
  • METHODS: We studied 103 cases of primary untreated endometrial carcinoma in which the p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptor antigens were investigated by an immunohistochemical method.
  • We evaluated the correlations among the immunohistochemical staining assessed by histoscore, and the age, grading, depth of invasion, stage of the neoplasia and extrauterine disease.
  • p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors were positive in 49 (48%), 81 (79%).
  • There was no clear association between immunohistochemical parameters and the age of patients. p53 and Ki-67 overexpression was found to be related to poor grade of differentiation, deeper myometrial invasion, advanced stage of neoplasia and extrauterine spread of disease.
  • Immunostaining for bcl-2 correlated inversely with FIGO stage, while c-erb-2 was overexpressed in tumors with deeper myometrial invasion.
  • Estrogen and progesterone receptor positive tumors showed a statistically significant association with clinicopathological parameters of better clinical outcome.
  • CONCLUSION: The overexpression of p53 and Ki-67 seems to indicate more malignant phenotype, while bcl-2 and c-erb-2 may have a limited role in the identification of high-risk tumors.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711961.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Zhong M, Wike LJ, Ryaby JT, Carney DH, Boyan BD, Schwartz Z: Thrombin peptide TP508 prevents nitric oxide mediated apoptosis in chondrocytes in the endochondral developmental pathway. Biochim Biophys Acta; 2008 Jan;1783(1):12-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apoptosis was assessed as a function of DNA fragmentation ([3H]-thymidine labeled DNA fragments), TUNEL staining, and cell viability using the MTT assay, as well as by assessing the Bcl-2/Bax mRNA and protein ratios and caspase-3 activity.
  • TP508 also regulated Bcl-2/Bax mRNA in a time and dose-dependent manner.
  • The Bcl-2/Bax mRNA ratio was 0.11 in the absence of TP508 at 1h and 4.95 at 7microg/ml TP508; by 3h the ratio was approximately 1 in both groups.
  • The Bcl-2/Bax protein ratio also increased by 63% at 1h.
  • [MeSH-minor] Animals. Cells, Cultured. Gene Expression Regulation / drug effects. NG-Nitroarginine Methyl Ester / pharmacology. Nitric Oxide Synthase / metabolism. Protein Kinase C / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023291.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / rusalatide acetate; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase; EC 2.7.11.13 / Protein Kinase C; EC 3.4.21.5 / Thrombin; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  •  go-up   go-down


22. Sbitti Y, Ismaili N, Bensouda Y, Kadiri H, Ichou M, Errihani H: Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy? J Hematol Oncol; 2010;3:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy?
  • Management of localized primary gastric B lymphoma (PGL) remains controversial.
  • MATERIALS: Records of all patients with a diagnosis of gastric lymphoma and which were treated in the National Institute of Oncology, between 1999 and 2006, were reviewed and patients fulfilling the following criteria were included in this study: histologically proven large-cell B lymphoma of the stomach; complete clinical information stage I/II disease according to the Musshoff staging; patients who received surgery followed by chemotherapy (group I) or chemotherapy alone (group II).
  • All clinical and pathological features were similar between the two groups, except that patients of group-I had significantly more stage II disease (P = 0.023) than that of group II.
  • Among the 52 patients who could be evaluated for response to chemotherapy, there were 45 who had complete response to treatment, 3 had partial response to the treatment and 4 had progressive disease.
  • CONCLUSION: Our data suggest that chemotherapy alone may be a reasonable alternative treatment for stage I/II gastric large-cell lymphoma but this result must be confirmed by prospective randomized clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):266-71 [1688927.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Oncology (Williston Park). 1993 Jan;7(1):29-32, 34; discussion 34, 37-8 [8420540.001]
  • [Cites] Am J Surg. 1993 May;165(5):561-5 [8488937.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1101-6 [8402104.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):275-80 [10355570.001]
  • [Cites] J Formos Med Assoc. 2006 Mar;105(3):194-202 [16520834.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):19-26 [20206105.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):28-37 [15213615.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975 Aug 8;83(4):323-41 [125960.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):27-34 [20206106.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71 [17339119.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1389-99 [3755645.001]
  • (PMID = 20569496.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2901218
  •  go-up   go-down


23. Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME, Serafino A, Torcia M, Cozzolino F, Ciriolo MR, Garaci E, Palamara AT: Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. J Biol Chem; 2009 Jun 5;284(23):16004-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication.
  • Previous reports have shown that various steps in the influenza A virus life cycle are impaired in cells expressing the antiapoptotic protein Bcl-2 (Bcl-2(+) cells).
  • We demonstrated a direct link between Bcl-2 and the reduced nuclear export of viral ribonucleoprotein (vRNP) complexes in these cells.
  • However, despite its negative impact on viral replication, Bcl-2 did not prevent host cells from undergoing virally triggered apoptosis.
  • In infected Bcl-2(+) cells, activated p38MAPK was found predominantly in the cytoplasm, colocalized with Bcl-2, and both Bcl-2 phosphorylation and virally induced apoptosis were diminished by specific inhibition of p38MAPK activity.
  • In contrast, in Bcl-2-negative (Bcl-2(-)) cells, which are fully permissive to viral infection, p38MAPK activity was predominantly nuclear, and its inhibition decreased vRNP traffic, phosphorylation of viral nucleoprotein, and virus titers in cell supernatants, suggesting that this kinase also contributes to the regulation of vRNP export and viral replication.
  • This could explain why in Bcl-2(+) cells, where p38MAPK is active in the cytoplasm, phosphorylating Bcl-2, influenza viral replication is substantially reduced, whereas apoptosis proceeds at rates similar to those observed in Bcl-2(-) cells.
  • Our findings suggest that the impact of p38MAPK on the influenza virus life cycle and the apoptotic response of host cells to infection depends on whether or not the cells express Bcl-2, highlighting the possibility that the pathological effects of the virus are partly determined by the cell type it targets.
  • [MeSH-major] Influenza A Virus, H1N1 Subtype / physiology. Kidney / physiology. Proto-Oncogene Proteins c-bcl-2 / genetics. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cell Line. DNA Primers. Dogs. Down-Regulation. Humans. Life Cycle Stages. Plasmids. Polymerase Chain Reaction. RNA, Small Interfering / genetics. Transfection. Virus Replication

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 2000 Jan;81(Pt 1):135-42 [10640551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6961-5 [1871110.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]
  • [Cites] J Virol. 1996 Jan;70(1):663-6 [8523590.001]
  • [Cites] J Virol. 1997 Dec;71(12):9690-700 [9371635.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):288-96 [9427762.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4175-81 [9574517.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):794-9 [9618384.001]
  • [Cites] Virology. 1998 Jun 20;246(1):1-23 [9656989.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):389-97 [10454214.001]
  • [Cites] Cell Mol Life Sci. 1999 Aug 15;55(10):1230-54 [10487205.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Apr 1;171(7):764-72 [15618464.001]
  • [Cites] J Infect Dis. 2005 May 15;191(10):1719-29 [15838800.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3222-8 [10706714.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):753-9 [11095980.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6751-8 [11118210.001]
  • [Cites] J Virol. 2001 Jan;75(1):408-19 [11119609.001]
  • [Cites] J Virol. 2001 Mar;75(6):2710-28 [11222695.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):301-5 [11231581.001]
  • [Cites] Leukemia. 2001 Jun;15(6):869-74 [11417471.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39027-36 [11495898.001]
  • [Cites] Virus Res. 2002 Mar 20;84(1-2):37-44 [11900837.001]
  • [Cites] J Gen Virol. 2002 Apr;83(Pt 4):723-34 [11907320.001]
  • [Cites] Trends Mol Med. 2003 Feb;9(2):46-52 [12615037.001]
  • [Cites] FASEB J. 2003 Apr;17(6):758-60 [12594179.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2717-28 [12773387.001]
  • [Cites] Vet Microbiol. 2003 Aug 29;95(1-2):1-13 [12860072.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):870-6 [12878192.001]
  • [Cites] Virus Res. 2003 Sep;95(1-2):3-12 [12921991.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4646-55 [12970177.001]
  • [Cites] J Virol. 2004 Feb;78(3):1263-70 [14722281.001]
  • [Cites] Appl Microbiol. 1968 Apr;16(4):588-94 [5647517.001]
  • [Cites] J Gen Virol. 1989 Sep;70 ( Pt 9):2421-31 [2778438.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):739-42 [8441470.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] J Virol. 1994 Jun;68(6):3667-73 [8189504.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1195-202 [8203460.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):200-4 [10602750.001]
  • [Cites] J Virol. 2005 Aug;79(16):10147-54 [16051807.001]
  • [Cites] J Virol. 2005 Sep;79(18):11788-800 [16140756.001]
  • [Cites] Brain Res Bull. 2006 Feb 15;68(6):406-13 [16459194.001]
  • [Cites] Cell Microbiol. 2006 Mar;8(3):375-86 [16469051.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21353-61 [16714293.001]
  • [Cites] FASEB J. 2006 Aug;20(10):1683-5 [16790527.001]
  • [Cites] Intervirology. 2007;50(2):99-107 [17139186.001]
  • [Cites] Virus Res. 2007 Mar;124(1-2):12-21 [17081640.001]
  • [Cites] J Virol. 2007 Dec;81(23):12730-9 [17881440.001]
  • [Cites] PLoS Pathog. 2008 May;4(5):e1000018 [18516228.001]
  • [Cites] J Virol. 2000 Feb;74(4):1781-6 [10644350.001]
  • (PMID = 19336399.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2708894
  •  go-up   go-down


24. Marmey B, Boix C, Barbaroux JB, Dieu-Nosjean MC, Diebold J, Audouin J, Fridman WH, Mueller CG, Molina TJ: CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol; 2006 Jan;37(1):68-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.
  • The mononuclear phagocyte system of human lymphoid tissue comprises macrophages and dendritic cells (DCs).
  • The heterogeneity of the non-DC mononuclear phagocyte population in human lymphoid tissue has been little addressed.
  • Here, we studied the expression of 2 monocyte-derived markers, CD14 and CD169 (sialoadhesin), in reactive human lymphoid tissue as well as in a series of 51 B-cell lymphomas by immunohistochemistry on paraffin-embedded tissue.
  • We confirmed that lymph node sinusoidal monocyte-derived cells were the only population staining for CD169.
  • Although most sinusoidal histiocytes also expressed CD14, monocyte-derived cells with phagocytosis such as erythrophagocytosis, anthracosis, or tingible bodies macrophage lacked CD14 and CD169.
  • Among B-cell lymphomas, splenic marginal zone lymphoma was the only one associated with an expansion of the CD14(+)CD169(+) cells in the cords.
  • With respect to nodal B-cell lymphomas, CD14(+) cells were rare among B-chronic lymphocytic leukemia, follicular lymphoma (FL), mantle cell lymphoma (MCL).
  • However, strikingly, we found a strong expansion of CD14(+)CD169(-) cells in numerous diffuse large B-cell lymphomas (DLBCLs), except in cases associated with numerous mitoses, apoptotic bodies, and tingible bodies macrophages.
  • When cultivated in granulocyte/macrophage colony stimulating factor/interleukin 4, DLBCL purified CD14(+) cells differentiate into plasmacytoid cells, expressing DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, suggesting dendritic cell differentiation potential.
  • [MeSH-major] Antigens, CD14 / metabolism. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Monocytes / metabolism. Receptors, Immunologic / metabolism. Spleen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Separation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Flow Cytometry. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymphadenitis / metabolism. Lymphadenitis / pathology. Sialic Acid Binding Ig-like Lectin 1

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360418.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1
  •  go-up   go-down


25. Sørensen RB, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, Andersen MH: Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother; 2007 Apr;56(4):527-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient.
  • Based on the detection of spontaneous immune responses in cancer patients with cancer of different origin, Bcl-X(L) was recently described as a highly interesting tumor antigen recognized by CD8 positive cytotoxic T lymphocytes.
  • To further characterize Bcl-X(L) as a tumor antigen we isolated and expanded Bcl-X(L) specific T cells from the peripheral blood of a breast cancer patient hosting a strong Bcl-X(L) specific T cell response.
  • We describe that HLA-A2 restricted Bcl-X(L) specific T cell clones very efficiently lyse peptide pulsed T2 cells.
  • Furthermore, tumor cell lines of different origin, i.e., breast cancer, colon cancer, and melanoma, are efficiently lysed in an HLA-dependent manner.
  • Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells.
  • Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Breast Neoplasms / immunology. Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology. bcl-X Protein / immunology
  • [MeSH-minor] Clone Cells. Cytotoxicity, Immunologic. Female. Flow Cytometry. HLA-A2 Antigen. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850344.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / bcl-X Protein
  •  go-up   go-down


26. Takada E, Hata K, Mizuguchi J: Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31. Exp Cell Res; 2006 Nov 15;312(19):3728-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31.
  • The cross-linking of B cell receptor (BCR) undergoes growth arrest, accompanied by apoptosis, in the CH31 and WEHI-231 B lymphoma cells, a model representing primary immature B cells.
  • In unstimulated cells, BimL protein was complexed with Bcl-x(L) and changed the partner to associate with Bax on the mitochondrial membrane after ligation of BCR, leading to initiation of apoptotic processes.
  • Retroviral transduction of BimL into WEHI-231 cells overexpressing dominant-negative form of JNK1 (dnJNK1) resulted in a comparable level of apoptotic cells to control cells, whereas the BimL-mediated apoptosis was partially prevented by Bcl-x(L).
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. Lymphoma, B-Cell / metabolism. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Animals. Antibodies, Anti-Idiotypic / administration & dosage. Apoptosis / immunology. Base Sequence. Biological Transport, Active. Cell Line, Tumor. DNA Primers / genetics. Immunoglobulin M. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. Receptors, Antigen, B-Cell / metabolism. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Transduction, Genetic. Up-Regulation. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007835.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Apoptosis Regulatory Proteins; 0 / Bax protein, mouse; 0 / Bcl-2-like protein 11; 0 / Bcl2l1 protein, mouse; 0 / DNA Primers; 0 / Immunoglobulin M; 0 / Membrane Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, B-Cell; 0 / Recombinant Proteins; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


27. Coupland SE, Joussen A, Anastassiou G, Stein H: Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report. Graefes Arch Clin Exp Ophthalmol; 2005 May;243(5):482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report.
  • PURPOSE: To report the clinical, histopathological and molecular biological findings of a primary extranodal marginal zone B-cell lymphoma (EMZL) of the uvea.
  • RESULTS: Histological examination of the chorioretinal biopsy demonstrated a dense infiltrate of small centrocyte-like cells, plasmacytoid tumour cells and occasional blasts.
  • The tumour cells were positive for CD20, showed monotypical expression for Ig-kappa and IgM, and a growth fraction of 10%.
  • Clonality analysis using IgH-PCR disclosed a monoclonal B-cell population.
  • Despite its rarity, ophthalmic pathologists should consider the diagnosis of a primary uveal EMZL when reviewing chorioretinal biopsies.
  • [MeSH-major] Choroid / pathology. Lymphoma, B-Cell / diagnosis. Retina / pathology. Uveal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] J Pathol. 2002 Jul;197(3):333-40 [12115879.001]
  • [Cites] Br J Ophthalmol. 1989 Oct;73(10):846-51 [2684263.001]
  • [Cites] Am J Ophthalmol. 1994 Oct 15;118(4):457-62 [7943123.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Aug;77(4):448-52 [10463420.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ophthalmology. 1987 Apr;94(4):397-406 [3295641.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Arch Ophthalmol. 1996 Jun;114(6):669-75 [8639077.001]
  • [Cites] Retina. 1999;19(4):343-6 [10458303.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):151-8 [10647734.001]
  • (PMID = 15586289.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


28. Meredith RF: Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S23-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
  • The two approved radioimmunotherapy agents, yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab, are being studied in a range of lymphoid malignancies, from low-grade to aggressive B-cell non-Hodgkin's lymphomas.
  • Studies of standard- and escalated-dose radioimmunotherapy with or without stem cell support are reviewed, as are radioimmunotherapy with other therapeutic modalities in these settings.
  • The results of these trials have important implications for clinical practice, and it is hoped that they will further clarify the optimal timing and dosing of these agents.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Antigens, CD20 / immunology. Clinical Trials as Topic. Humans. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 47
  •  go-up   go-down


29. Filippi AR, Franco P, Galliano M, Ricardi U: Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiat Oncol; 2006;1:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation.
  • Mantle Cell Lymphoma (MCL) is a well-known histological and clinical subtype of B-cell non-Hodgkin's Lymphomas.
  • It is usually characterized by an aggressive disease course, presenting with advanced stage disease at diagnosis and with low response rates to therapy.
  • We herein report a case of MCL with splenomegaly and peripheral blood involvement as main clinical features.
  • Mainly advocated mechanisms responsible for this phenomenon are considered direct radiation-induced apoptotic cell death, immune modulation via proportional changes of lymphocyte subsets due to known differences in intrinsic radiosensitivity and a radiation-induced cytokine release.
  • The peculiar intrinsic radiosensitivity pattern of lymphoid cells could probably be explained by well-defined individual genetic and molecular features.
  • In this context, among NHLs, MCL subtype has the highest rate of ATM (Ataxia Teleangiectasia Mutated) inactivation.
  • While the ATM gene is thought to play a key-role in detecting radiation-induced DNA damage (especially Double Strand Breaks), recent in vitro data support the hypothesis that ATM loss may actually contribute to the radiosensitivity of MCL cells.
  • [MeSH-major] Cell Cycle Proteins / genetics. Chromosome Deletion. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / radiotherapy. Protein-Serine-Threonine Kinases / genetics. Spleen / radiation effects. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Mar;58(3):235-46 [11230883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8 [10706620.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):401-8 [11818206.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):237-45 [11863220.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):178-83 [12714892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5372-7 [12697903.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7905-12 [12970738.001]
  • [Cites] Tumori. 1982 Dec 31;68(6):511-4 [6820205.001]
  • [Cites] Acta Haematol. 1983;70(1):59-62 [6408868.001]
  • [Cites] Radiother Oncol. 1985 Aug;4(1):45-54 [3898236.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Dec;48(6):943-61 [3877700.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1204-7 [2427184.001]
  • [Cites] Am J Hematol. 1989 Mar;30(3):188-9 [2916562.001]
  • [Cites] Eur J Haematol. 1991 Apr;46(4):202-4 [2015875.001]
  • [Cites] Br J Haematol. 1990 Oct;76(2):305-6 [2094335.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1729-34 [1389495.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):65-71 [8172197.001]
  • [Cites] Br J Radiol. 1995 Sep;68(813):997-1003 [7496700.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):395-8 [9322903.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] Blood Rev. 1999 Sep;13(3):163-70 [10527268.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):520-8 [15992701.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6409-14 [16155027.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):113-8 [16413041.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3262-4 [10556216.001]
  • [Cites] Blood. 2002 Jan 1;99(1):238-44 [11756177.001]
  • (PMID = 16956411.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1569379
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


30. Flygare J, Gustafsson K, Kimby E, Christensson B, Sander B: Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett; 2005 Dec 19;579(30):6885-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
  • We have earlier reported overexpression of the central and peripheral cannabinoid receptors CB1 and CB2 in mantle cell lymphoma (MCL), a B cell non-Hodgkin lymphoma.
  • In this study, treatment with cannabinoid receptor ligands caused a decrease in viability of MCL cells, while control cells lacking CB1 were not affected.
  • Moreover, treatment with the CB1/CB2 agonist Win-55,212-2 caused a decrease in long-term growth of MCL cells in culture.
  • [MeSH-major] Cell Death / drug effects. Cell Division / drug effects. Lymphoma, Mantle-Cell / pathology. Receptors, Cannabinoid / metabolism
  • [MeSH-minor] Animals. Arachidonic Acids / pharmacology. Benzoxazines. Biopsy. Breast Neoplasms / pathology. Cannabinoid Receptor Agonists. Cannabinoid Receptor Antagonists. Cannabinoids / pharmacology. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Cell Transformation, Viral. Cells, Cultured. Dose-Response Relationship, Drug. Endocannabinoids. Female. Flow Cytometry. Humans. Leukemia, Plasma Cell / pathology. Ligands. Mice. Morpholines / pharmacology. Naphthalenes / pharmacology. Piperidines / pharmacology. Polyunsaturated Alkamides. Pyrazoles / pharmacology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337199.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Benzoxazines; 0 / Cannabinoid Receptor Agonists; 0 / Cannabinoid Receptor Antagonists; 0 / Cannabinoids; 0 / Endocannabinoids; 0 / Ligands; 0 / Morpholines; 0 / Naphthalenes; 0 / Piperidines; 0 / Polyunsaturated Alkamides; 0 / Pyrazoles; 0 / Receptors, Cannabinoid; 134959-51-6 / Win 55212-2; 158681-13-1 / rimonabant; 94421-68-8 / anandamide
  •  go-up   go-down


31. Grillo-López AJ: 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Semin Oncol; 2005 Feb;32(1 Suppl 1):S44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
  • Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) was approved in the United States in 2002 for patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory disease, and in Europe in 2003.
  • This agent has yielded good results in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, for whom limited treatment options are available.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy. Radiopharmaceuticals / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786025.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


32. Eissing T, Waldherr S, Allgöwer F, Scheurich P, Bullinger E: Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J; 2007 May 1;92(9):3332-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores.
  • [MeSH-major] Apoptosis / physiology. Cell Membrane Permeability / physiology. Ion Channels / metabolism. Mitochondria / physiology. Mitochondrial Membrane Transport Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Animals. Cell Survival. Computer Simulation. Humans. Models, Biological

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13210-5 [15340155.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36892-7 [15208304.001]
  • [Cites] Cell. 2004 Sep 17;118(6):675-85 [15369668.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6807-20 [15501957.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27084-90 [9765224.001]
  • [Cites] FEBS J. 2005 Aug;272(16):4071-9 [16098190.001]
  • [Cites] Biophys J. 2006 Mar 1;90(5):1546-59 [16339882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8697-702 [16735474.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1310-7 [16691212.001]
  • [Cites] Syst Biol (Stevenage). 2005 Dec;152(4):221-8 [16986264.001]
  • [Cites] EMBO J. 2006 Sep 20;25(18):4338-49 [16932741.001]
  • [Cites] Syst Biol (Stevenage). 2005 Mar;2(1):35-41 [17091581.001]
  • [Cites] PLoS Comput Biol. 2006 Sep 15;2(9):e120 [16978046.001]
  • [Cites] Biosystems. 2007 Nov-Dec;90(3):591-601 [17314003.001]
  • [Cites] Cell Death Differ. 1999 Nov;6(11):1054-9 [10578173.001]
  • [Cites] Cell Death Differ. 1999 Nov;6(11):1081-6 [10578177.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11345-51 [11801595.001]
  • [Cites] BMC Bioinformatics. 2002 Dec 13;3:38 [12482327.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1822-7 [14766974.001]
  • [CommentOn] Biophys J. 2006 Mar 1;90(5):1546-59 [16339882.001]
  • (PMID = 17277182.001).
  • [ISSN] 0006-3495
  • [Journal-full-title] Biophysical journal
  • [ISO-abbreviation] Biophys. J.
  • [Language] eng
  • [Publication-type] Comment; Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ion Channels; 0 / Mitochondrial Membrane Transport Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0 / mitochondrial permeability transition pore
  • [Other-IDs] NLM/ PMC1852357
  •  go-up   go-down


33. Ke B, Shen XD, Gao F, Qiao B, Ji H, Busuttil RW, Volk HD, Kupiec-Weglinski JW: Small interfering RNA targeting heme oxygenase-1 (HO-1) reinforces liver apoptosis induced by ischemia-reperfusion injury in mice: HO-1 is necessary for cytoprotection. Hum Gene Ther; 2009 Oct;20(10):1133-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of HO-1 siRNA significantly increased local neutrophil accumulation and the frequency of apoptotic cells.
  • Mice treated with HO-1 siRNA were characterized by increased caspase-3 activity and reduced HO-1 expression, whereas those given Ad-HO-1 showed decreased caspase-3 activity and increased HO-1/Bcl-2/Bcl-x(L), data confirmed by use of an in vitro cell culture system.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 1;164(11):5739-45 [10820251.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1015-26 [11015442.001]
  • [Cites] Toxicol Sci. 2000 Nov;58(1):109-17 [11053547.001]
  • [Cites] Hepatology. 2001 Feb;33(2):397-405 [11172341.001]
  • [Cites] Cell. 2001 Mar 23;104(6):805-8 [11290317.001]
  • [Cites] Transplantation. 2002 Jan 27;73(2):287-92 [11821745.001]
  • [Cites] Hum Gene Ther. 2002 Jul 1;13(10):1189-99 [12133272.001]
  • [Cites] Transplantation. 2002 Jul 15;74(1):96-102 [12134106.001]
  • [Cites] Transplantation. 2002 Oct 15;74(7):905-12 [12394829.001]
  • [Cites] FEBS Lett. 2002 Dec 4;532(1-2):227-30 [12459495.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):401-6 [12590264.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Aug;18(8):891-902 [12859717.001]
  • [Cites] Trends Immunol. 2003 Aug;24(8):449-55 [12909459.001]
  • [Cites] Am J Transplant. 2003 Sep;3(9):1076-82 [12919086.001]
  • [Cites] Gastroenterology. 2003 Oct;125(4):1246-57 [14517806.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):326-30 [14758366.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10677-84 [14688267.001]
  • [Cites] Surgery. 2004 Aug;136(2):390-400 [15300206.001]
  • [Cites] Virology. 1973 Apr;52(2):456-67 [4705382.001]
  • [Cites] J Pharmacol Methods. 1985 Nov;14(3):157-67 [2997548.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(23):7865-9 [3865203.001]
  • [Cites] Transplantation. 1993 Jun;55(6):1265-72 [7685932.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1331-41 [8879205.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1997;37:517-54 [9131263.001]
  • [Cites] EMBO J. 1997 Aug 1;16(15):4639-49 [9303308.001]
  • [Cites] Biochem J. 1997 Aug 15;326 ( Pt 1):1-16 [9337844.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1652-60 [9620339.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1073-7 [9734404.001]
  • [Cites] Nat Med. 1998 Dec;4(12):1392-6 [9846576.001]
  • [Cites] Oncogene. 1998 Dec 31;17(26):3401-15 [10030664.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1012-5 [10083450.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):173-8 [15538359.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7115-9 [15585830.001]
  • [Cites] Biochem J. 2005 Jan 15;385(Pt 2):537-44 [15554901.001]
  • [Cites] Transplantation. 2005 Jan 27;79(2):240-3 [15665774.001]
  • [Cites] Gene Ther. 2005 Jun;12(12):965-73 [15729369.001]
  • [Cites] Clin Chim Acta. 2006 Mar;365(1-2):270-8 [16242122.001]
  • [Cites] Exp Mol Pathol. 2006 Aug;81(1):48-54 [16443218.001]
  • [Cites] J Gene Med. 2006 Jul;8(7):889-900 [16652398.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2099-108 [16796725.001]
  • [Cites] Cardiovasc Res. 2007 Oct 1;76(1):132-40 [17601517.001]
  • [Cites] Liver Transpl. 2007 Oct;13(10):1435-43 [17902130.001]
  • [Cites] J Clin Invest. 1999 Dec;104(11):1631-9 [10587527.001]
  • [Cites] Mol Med. 2008 May-Jun;14(5-6):337-45 [18292799.001]
  • [Cites] Apoptosis. 2008 Aug;13(8):1013-21 [18561025.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H801-6 [18567706.001]
  • (PMID = 19534599.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI23847; United States / NIAID NIH HHS / AI / AI42223; United States / NIDDK NIH HHS / DK / R01 DK062357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / bcl-X Protein; EC 1.14.99.3 / Heme Oxygenase-1; EC 2.6.1.1 / Aspartate Aminotransferases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2829285
  •  go-up   go-down


34. Li YC, Lin HJ, Yang JH, Yang JS, Ho HC, Chang SJ, Hsai TC, Lu HF, Huang AC, Chung JG: Baicalein-induced apoptosis via endoplasmic reticulum stress through elevations of reactive oxygen species and mitochondria dependent pathway in mouse-rat hybrid retina ganglion cells (N18). Neurochem Res; 2009 Mar;34(3):418-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baicalein-induced apoptosis via endoplasmic reticulum stress through elevations of reactive oxygen species and mitochondria dependent pathway in mouse-rat hybrid retina ganglion cells (N18).
  • Studies were designed to investigate the effects of baicalein on mouse-rat hybrid retina ganglion cells (N18) to better understand its effect on apoptosis and apoptosis-related genes in vitro.
  • Cell viability, reactive oxygen species (ROS), cytoplasmic Ca2+, mitochondrial membrane potential (MMP), apoptosis induction, and caspases-3 activity were examined by flow cytometric assay.
  • Apoptosis-associated proteins such as p53, Bax, Bcl-2, cytochrome c, and caspase-3 were examined by Western blot.
  • We demonstrated the increase in the levels of p53, Bax, and cytochrome c and decrease in the level of Bcl-2, which are associated with the induction of apoptotic cell death after 24 h treatment with baicalein in N18 cells.
  • We also demonstrated a release of the cytochrome c from mitochondria into cytosol and an activation of caspase-3, which led to the occurrence of apoptosis in N18 cells treated with baicalein by Western blot.
  • Pretreatment was conducted with BAPTA (intracellular calcium chelator) in baicalein-treated cells, the decline of MMP was recovered, and the increase in the level of cytoplasmic Ca2+ was suppressed, and the proportion of apoptosis was also markedly diminished.
  • In conclusion, our data suggests that oxidative stress and cellular Ca2+ modulates the baicalein-induced cell death via a Ca2+-dependent mitochondrial death pathway in N18 cells.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Apoptosis. Endoplasmic Reticulum / metabolism. Flavanones / pharmacology. Hybrid Cells / drug effects. Mitochondria / physiology. Reactive Oxygen Species / metabolism. Retinal Ganglion Cells / drug effects
  • [MeSH-minor] Animals. Cell Line. Mice. Rats. Signal Transduction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 30;296(4):942-8 [12200139.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):691-704 [15505412.001]
  • [Cites] Biotechniques. 1997 Sep;23(3):525-31 [9298227.001]
  • [Cites] Pharmacol Res. 2001 Feb;43(2):173-8 [11243719.001]
  • [Cites] J Ethnopharmacol. 2001 Oct;77(2-3):183-8 [11535362.001]
  • [Cites] Neuroreport. 2001 Jul 20;12(10):2199-202 [11447334.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):29831-7 [10514462.001]
  • [Cites] Planta Med. 2002 Mar;68(3):268-71 [11914968.001]
  • [Cites] Cardiovasc Res. 2000 Apr;46(1):126-38 [10727661.001]
  • [Cites] Am J Chin Med. 1996;24(1):31-6 [8739179.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 3;1571(3):201-10 [12090934.001]
  • [Cites] J Cell Biol. 1997 Dec 1;139(5):1317-24 [9382876.001]
  • [Cites] Cytometry. 2000 Feb 15;42(1):74-8 [10679746.001]
  • [Cites] Ann Allergy. 1988 Dec;61(6 Pt 2):53-7 [3061322.001]
  • [Cites] Arch Biochem Biophys. 1993 Oct;306(1):261-6 [8215413.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):309-17 [12084473.001]
  • [Cites] Neurochem Res. 2006 Mar;31(3):383-93 [16733814.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Biochim Biophys Acta. 1999 Nov 16;1472(3):643-50 [10564778.001]
  • [Cites] Eur J Pharmacol. 2007 Mar 15;559(1):14-20 [17223102.001]
  • [Cites] Neuron. 1997 Aug;19(2):453-63 [9292733.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1415-20 [8068938.001]
  • [Cites] Int J Mol Med. 2004 Oct;14(4):627-32 [15375593.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:331-4 [15033745.001]
  • [Cites] Planta Med. 2002 Apr;68(4):302-6 [11988851.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):2861-5 [11062694.001]
  • [Cites] Exp Mol Med. 2006 Dec 31;38(6):616-24 [17202837.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Biochem Pharmacol. 2001 Dec 15;62(12 ):1653-60 [11755119.001]
  • [Cites] Drug Metab Dispos. 2006 Feb;34(2):296-304 [16280456.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:648-58 [15033806.001]
  • [Cites] Toxicol Sci. 2000 Feb;53(2):340-51 [10696782.001]
  • [Cites] Toxicol Lett. 2000 Mar 15;112-113:41-8 [10720711.001]
  • [Cites] Nutr Cancer. 2000;38(2):200-8 [11525598.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2721-7 [11980674.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1349-54 [11532854.001]
  • [Cites] Am J Chin Med. 1998;26(3-4):311-23 [9862019.001]
  • [Cites] Free Radic Biol Med. 2001 Feb 15;30(4):433-46 [11182299.001]
  • (PMID = 18661233.001).
  • [ISSN] 1573-6903
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Flavanones; 0 / Reactive Oxygen Species; 49QAH60606 / baicalein
  •  go-up   go-down


35. Chen CA, Tsai JC, Su PW, Lai YH, Chen HC: Signaling and regulatory mechanisms of integrinalpha3beta1 on the apoptosis of cultured rat podocytes. J Lab Clin Med; 2006 Jun;147(6):274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Integrin is the major adhesion molecule for the attachment of podocytes to the glomerular basement membrane, and integrins have been shown to play a major role in the regulation of cell survival.
  • Cytochrome c was examined by immunohistochemical stain, and Fas, Fas ligand, Bax, Bcl-2, and ERK activation (p-ERK/ERK) were analyzed by Western blotting analysis.
  • The results demonstrated that the integrin antagonist, Gly-Arg-Gly-Asp (GRGD), increased the percentage of cells with apoptosis (from 0.9+/-0.5% to 27.2+/-9.9%, P < 0.01).
  • In GRGD-treated cells, cytochrome c was found released into cytoplasm by immunohistochemical study and the Bax expression was upregulated, whereas Bcl-2 expression was not changed.
  • Fas was not expressed in both control and GRGD-treated podocytes, although Fas ligand was upregulated in GRGD-treated cells.
  • ERK activation was also found to be increased in GRGD-treated cells.
  • The results indicated that alpha3beta1integrin is necessary for the prevention of the apoptosis of cultured rat podocytes, and that the signaling involves the Bax, Bcl-2, and cytochrome c pathways.
  • [MeSH-minor] Animals. Antigens, CD95 / metabolism. Cell Adhesion / physiology. Cells, Cultured. Cytochromes c / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Fas Ligand Protein. In Situ Nick-End Labeling. Membrane Glycoproteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factors / metabolism. bcl-2-Associated X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750664.001).
  • [ISSN] 0022-2143
  • [Journal-full-title] The Journal of laboratory and clinical medicine
  • [ISO-abbreviation] J. Lab. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Integrin alpha3beta1; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tnfsf6 protein, rat; 0 / Tumor Necrosis Factors; 0 / bcl-2-Associated X Protein; 9007-43-6 / Cytochromes c; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


36. Fernández Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, Lowe SW, Soengas MS: Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res; 2005 Jul 15;65(14):6294-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
  • Using bortezomib as a prototypic proteasome inhibitor, we have identified a novel and critical role of the proteasome in the maintenance of the malignant phenotype of melanoma cells that could have direct translational implications.
  • Thus, melanoma cells from early, intermediate, and late stages of the disease could not sustain proteasome inhibition and underwent an effective activation of caspase-dependent and -independent death programs.
  • This effect was tumor cell selective, because under similar conditions, normal melanocytes remained viable.
  • Intriguingly, and despite of interfering with a cellular machinery in charge of controlling the half-life of the vast majority of cellular proteins, bortezomib did not promote a generalized disruption of melanoma-associated survival factors (including NF-kappaB, Bcl-2, Bcl-x(L), XIAP, TRAF-2, or FLIP).
  • Instead, we identified a dramatic induction in vitro and in vivo of the BH3-only protein Noxa in melanoma cells (but not in normal melanocytes) in response to proteasome inhibition.
  • In summary, our results revealed Noxa as a new biomarker to gauge the efficacy of bortezomib specifically in tumor cells, and provide a new strategy to overcome tumor chemoresistance.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024631.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA10456; United States / NCI NIH HHS / CA / CA13106; United States / NCI NIH HHS / CA / R01 CA107237
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / NF-kappa B; 0 / PMAIP1 protein, human; 0 / Pmaip1 protein, mouse; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K: Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood; 2005 Feb 1;105(3):1246-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells.
  • Bcr-Abl-expressing primary or cultured leukemia cells display high levels of the antiapoptotic heat shock protein (hsp) 70 and are resistant to cytarabine (Ara-C), etoposide, or Apo-2L/TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis.
  • Conversely, a stable expression of the cDNA of hsp70 in the reverse orientation attenuated not only hsp70 but also signal transducers and activators of transcription 5 (STAT5) and Bcl-x(L) levels.
  • Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.
  • HL-60/hsp70 cells exhibited increased levels and DNA binding activity of STAT5, which was associated with high levels of Pim-2 and Bcl-x(L) and resistance to apoptosis.
  • Expression of the dominant negative (DN) STAT5 resensitized HL-60/hsp70 cells to cytarabine, etoposide, and Apo-2L/TRAIL-induced apoptosis.
  • Collectively, these findings suggest that hsp70 inhibits apoptosis upstream and downstream of the mitochondria and is a promising therapeutic target for reversing drug-resistance in chronic myeloid leukemia-blast crisis and acute myeloid leukemia cells.
  • [MeSH-minor] Cell Line, Tumor. DNA Primers. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. HL-60 Cells. Humans. Jurkat Cells. Leukemia, Myeloid, Acute. Milk Proteins / genetics. Milk Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. STAT5 Transcription Factor. Trans-Activators / genetics. Trans-Activators / metabolism. bcl-2-Associated X Protein. bcl-X Protein

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388581.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / HSP70 Heat-Shock Proteins; 0 / Milk Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / STAT5 Transcription Factor; 0 / Trans-Activators; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


38. Linzmann H, Brunnberg L, Gruber AD, Klopfleisch R: A neurotropic lymphoma in the brachial plexus of a cat. J Feline Med Surg; 2009 Jun;11(6):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A neurotropic lymphoma in the brachial plexus of a cat.
  • A 7-year-old, intact male domestic shorthair cat was presented with a progressive, non-weight-bearing lameness of the right forelimb.
  • Further clinical, radiological and pathological findings lead to a diagnosis of a primary, neurotropic B-cell lymphoma in the brachial plexus.
  • [MeSH-major] Brachial Plexus. Cat Diseases / diagnosis. Lymphoma, B-Cell / veterinary. Peripheral Nervous System Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135398.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Kanthan R, Senger JL, Diudea D: Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol; 2010;8:60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.
  • AIM: The aim of our study was to evaluate survival outcomes in malignant mixed Mullerian tumors (MMMT) of the uterus with respect to the role of cell cycle and apoptotic regulatory proteins in the carcinomatous and sarcomatous components.
  • Immunohistochemical expression of Bad, Mcl-1, bcl-x, bak, mdm2, bax, p16, p21, p53, p27, EMA, Bcl-2, Ki67 and PCNA was correlated with clinico-pathological data including survival outcomes.
  • RESULTS: Histopathological examination confirmed malignant epithelial component with homologous (12 cases) and heterologous (11 cases) sarcomatous elements.
  • CONCLUSIONS: Our study supports that a) cell cycle and apoptotic regulatory protein dysregulation is an important pathway for tumorigenesis and b) p53 is an important immunoprognostic marker in MMMT of the uterus.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Cell Cycle Proteins / metabolism. Mixed Tumor, Mullerian / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Metastasis. Prognosis


40. Wang G, Zhou D, Wang C, Gao Y, Zhou Q, Qian G, DeCoster MA: Hypoxic preconditioning suppresses group III secreted phospholipase A2-induced apoptosis via JAK2-STAT3 activation in cortical neurons. J Neurochem; 2010 Aug;114(4):1039-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we demonstrate that sPLA(2) III significantly decreased production of Bcl-xl and the ratio of Bcl-xl/Bax, and increased expression of Bax, cleaved caspase 3, and cleaved alpha-Fodrin in primary neuronal culture.
  • HPC prevented the sPLA(2) III-induced decreases in production of Bcl-xl and the ratio of Bcl-xl/Bax, and increases in expression of Bax, cleaved caspase 3, and alpha-Fodrin.
  • Our results suggest that sPLA(2) III-induced neuronal apoptosis is likely because of its alterations in expression and activity of Bcl-xl, Bax, caspase 3, and its target gene fodrin; and that HPC-produced neuroprotection against the sPLA(2) III toxicity is mediated via JAK-STAT signal pathways that regulate the expression of Bcl-xl, Bax, and cleaved caspase 3 in cultured cortical neurons.
  • [MeSH-minor] Animals. Apoptosis Regulatory Proteins / antagonists & inhibitors. Apoptosis Regulatory Proteins / metabolism. Cells, Cultured. Nerve Degeneration / enzymology. Nerve Degeneration / metabolism. Nerve Degeneration / pathology. Nerve Degeneration / prevention & control. Rats. Rats, Sprague-Dawley. Signal Transduction / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492356.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR016456
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; EC 2.7.10.2 / Jak2 protein, rat; EC 2.7.10.2 / Janus Kinase 2; EC 3.1.1.4 / Group III Phospholipases A2
  •  go-up   go-down


41. Lukyanova NY: Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells. Exp Oncol; 2010 Mar;32(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells.
  • METHODS: In current study human MCF-7 breast cancer cells and A2780 ovarian cancer cells sensitive to anticancer drugs were used.
  • To access the viability of cells, we applied 3-[4,5-dimethylthiazol-2-1]-2,5-diphenyltetrazolium bromide colorimetric assay (MTT-test).
  • Expression of Bcl-2, p-glycoprotein (P-gp), glutathione S-transferase (GST) and E-cadherin was studied by immunocytochemistry.
  • RESULTS: A2780 and MCF-7 cells were treated by homocysteine.
  • It was shown that every next treatment with homocysteine (up to 5th) decreased the sensitivity of A2780 and MCF-7 cells to cytotoxic drugs.
  • Immunocytochemical study of molecular profile of A2780 and MCF-7 cells after long-term cultivation with homocysteine has been carried out and has revealed that such treatment resulted in the induction of Bcl-2, P-gp, GST and E-cadherin expression.
  • This indicates that incubation of studied cells with homocysteine leads to simultaneous induction of expression of drug resistance markers to cisplatin and doxorubicin.
  • CONCLUSION: Cultivation of MCF-7 and A2780 cells with homocysteine leads to simultaneous development of resistance to doxorubicine and cisplatin.
  • The development of drug resistance is diverse for different drugs and varies among cell lines.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Homocysteine / pharmacology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cadherins / metabolism. Cell Line, Tumor. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. P-Glycoprotein / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism


42. Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y: TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology; 2006 Jul;44(1):205-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
  • Previous works showed that loss of TIP30, also called CC3, a putative tumor suppressor, increased the incidence of hepatocellular carcinoma in mice, and some clinical samples of human HCC tissues had aberrant expression of TIP30.
  • Here, we report that the introduction of TIP30 by an adenovirus vector into HCC cell lines that had decreased expressions of TIP30 inhibited cell proliferation, decreased anchorage-dependent growth, suppressed invasion through the extracellular matrix, and inhibited tumorigenesis in nude mice.
  • Moreover, exogenous expression of Tip30 sensitized HCC cells to cytotoxic drugs and to apoptosis induced by tumor necrosis factor-related ligands in vitro.
  • Ectopic expression of TIP30 in HCC cells enhanced p53 expression and decreased Bcl-2/Bcl-xL expression.
  • [MeSH-major] Acetyltransferases / pharmacology. Antimetabolites, Antineoplastic / pharmacology. Carcinoma, Hepatocellular / pathology. Cell Proliferation / drug effects. Fluorouracil / pharmacology. Liver Neoplasms / pathology. Transcription Factors / pharmacology
  • [MeSH-minor] Adenoviridae. Animals. Apoptosis. Blotting, Western. Carcinogenicity Tests. Cell Line, Tumor. DNA, Neoplasm / genetics. Flow Cytometry. Gene Expression Regulation, Neoplastic. Genetic Vectors. Humans. Immunohistochemistry. In Vitro Techniques. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799960.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / Transcription Factors; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.48 / HTATIP2 protein, human; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Sawatzky DA, Willoughby DA, Colville-Nash PR, Rossi AG: The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo. Am J Pathol; 2006 Jan;168(1):33-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo.
  • Inflammatory cell recruitment, activation, and apoptosis are highly regulated processes involving several checkpoints controlling the resolution of inflammation.
  • We investigated the role of the mitogen-activated protein kinase (MAPK) signaling pathway (ie, ERK1/2) and apoptosis-regulating Bcl-2 family members (ie, Bcl-x(L) and Bax) in the resolution of a rat carrageenan-induced pleurisy model.
  • In conclusion, this study shows that ERK1/2, Bax, and Bcl-x(L) play important functional roles in the resolution phase of the acute inflammatory response in vivo by influencing apoptosis.
  • [MeSH-major] Apoptosis / physiology. Extracellular Signal-Regulated MAP Kinases / metabolism. Inflammation / physiopathology. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Carrageenan / adverse effects. Disease Models, Animal. Enzyme Inhibitors / pharmacology. Flavonoids / pharmacology. Flow Cytometry. Macrophages / drug effects. Macrophages / immunology. Male. Neutrophils / drug effects. Neutrophils / immunology. Pleurisy / etiology. Pleurisy / immunology. Rats. Rats, Inbred Lew

  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunology. 2004 Sep;113(1):1-14 [15312130.001]
  • [Cites] Mol Pharmacol. 2004 Sep;66(3):683-93 [15322261.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 3;321(4):961-6 [15358121.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Int Rev Cytol. 1980;68:251-306 [7014501.001]
  • [Cites] Carcinogenesis. 1990 May;11(5):847-53 [2139818.001]
  • [Cites] Agents Actions. 1991 Mar;32(3-4):283-8 [1650522.001]
  • [Cites] Transplantation. 1992 Apr;53(4):808-15 [1566346.001]
  • [Cites] Transplantation. 1994 Feb 27;57(4):563-8 [8116042.001]
  • [Cites] Br J Pharmacol. 1994 Nov;113(3):693-8 [7532080.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):962 [7877665.001]
  • [Cites] Lancet. 1995 Aug 19;346(8973):506 [7637500.001]
  • [Cites] Am J Pathol. 1995 Aug;147(2):278-92 [7543732.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2577-85 [8805660.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Dec;279(3):1453-61 [8968371.001]
  • [Cites] Nature. 1997 Jun 19;387(6635):773-6 [9194558.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):5070-8 [9366435.001]
  • [Cites] Nature. 1997 Nov 27;390(6658):350-1 [9389474.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):890-8 [9466984.001]
  • [Cites] Inflammation. 1998 Feb;22(1):67-82 [9484651.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):101-9 [9649464.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18623-32 [9660836.001]
  • [Cites] J Leukoc Biol. 1998 Oct;64(4):537-45 [9766635.001]
  • [Cites] J Leukoc Biol. 1998 Oct;64(4):555-62 [9766637.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1475-82 [9779994.001]
  • [Cites] J Clin Invest. 1999 Mar;103(6):851-8 [10079106.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):18100-6 [10364264.001]
  • [Cites] Nat Med. 1999 Jun;5(6):698-701 [10371510.001]
  • [Cites] Proc Soc Exp Biol Med. 1962 Dec;111:544-7 [14001233.001]
  • [Cites] Clin Exp Allergy. 2004 Nov;34(11):1701-6 [15544593.001]
  • [Cites] J Cell Biol. 2004 Dec 20;167(6):1161-70 [15611337.001]
  • [Cites] FEBS Lett. 2002 Jun 5;520(1-3):145-52 [12044887.001]
  • [Cites] Immunol Rev. 2002 Aug;186:8-18 [12234358.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):787-95 [12360216.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1911-2 [12471242.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):846-52 [12490957.001]
  • [Cites] Adv Exp Med Biol. 2002;507:33-40 [12664561.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):352-7 [12652309.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):175-83 [10643714.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):4286-91 [10754327.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2198-204 [10925307.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] Clin Exp Immunol. 2001 Apr;124(1):16-20 [11359438.001]
  • [Cites] Gut. 2001 Jul;49(1):35-41 [11413108.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Aug 15;164(4):688-97 [11520738.001]
  • [Cites] J Leukoc Biol. 2001 Oct;70(4):649-58 [11590203.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1861-8 [11823520.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14884-93 [11842088.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1070-4 [12821152.001]
  • [Cites] Mol Cell Biochem. 2003 Apr;246(1-2):193-6 [12841362.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):412-9 [12901951.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):717-26 [12951578.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4672-9 [14568942.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2269-71 [14563690.001]
  • [Cites] Cell Signal. 2004 Jul;16(7):801-10 [15115659.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):401-16 [15136788.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):7053-9 [15153527.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):115-26 [15215167.001]
  • [Cites] J Cell Physiol. 2005 Mar;202(3):642-53 [15316926.001]
  • [Cites] Transplantation. 2005 Apr 15;79(7):846-50 [15818329.001]
  • [CommentIn] Am J Pathol. 2006 May;168(5):1762; author reply 1762-3 [16651640.001]
  • (PMID = 16400007.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; 9000-07-1 / Carrageenan; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ PMC1592663
  •  go-up   go-down


44. Yu YL, Chiang YJ, Chen YC, Papetti M, Juo CG, Skoultchi AI, Yen JJ: MAPK-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. J Biol Chem; 2005 Aug 19;280(33):29533-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAPK-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival.
  • In the interleukin 3-dependent hematopoietic cell line Ba/F3, inhibition of mitogen-activated protein kinase, a member of the MAPK/c-Jun N-terminal kinase/stress-activated protein kinase kinase family that plays an important role in cell growth and death control, rapidly leads to severe apoptosis.
  • Here we report that, upon interleukin-3 stimulation of Ba/F3 cells, the transcription factor GATA-1 is strongly phosphorylated at residue serine 26 by a MAPK-dependent pathway.
  • Further characterization of GATA-1 phosphorylation site mutants revealed that the antiapoptotic function of GATA-1 is strongly dependent upon its phosphorylation at the Ser-26 position and is probably mediated through its up-regulation of Bcl-X(L) expression.
  • Taken together, our data demonstrate that MAPK-dependent GATA-1 phosphorylation is important for its transactivation of the E4bp4 gene, Bcl-X(L) expression and cell survival.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1264-73 [10666199.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16589-96 [8206977.001]
  • [Cites] Genes Dev. 2001 Oct 1;15(19):2503-8 [11581155.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7460-9 [11585926.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25446-56 [11948183.001]
  • [Cites] Curr Opin Cell Biol. 1994 Jun;6(3):415-24 [7917334.001]
  • [Cites] Protein Expr Purif. 1994 Dec;5(6):587-94 [7858429.001]
  • [Cites] Development. 1995 Jan;121(1):163-72 [7867497.001]
  • [Cites] J Biol Chem. 1995 Feb 24;270(8):4101-7 [7876160.001]
  • [Cites] J Biol Chem. 1995 Jun 23;270(25):15320-6 [7541039.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9623-7 [7568185.001]
  • [Cites] J Biol Chem. 1996 May 17;271(20):11684-8 [8662643.001]
  • [Cites] Oncogene. 1997 Jan 9;14(1):123-31 [9010239.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4750-7 [9144489.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Genes Dev. 1999 Jan 15;13(2):163-75 [9925641.001]
  • [Cites] Nucleic Acids Res. 1999 Feb 15;27(4):1168-75 [9927752.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2569-77 [10194436.001]
  • [Cites] Blood. 1999 Jul 1;94(1):87-96 [10381501.001]
  • [Cites] Gene. 1999 Jul 8;234(2):297-305 [10395902.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):6195-206 [10454566.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26563-71 [10473620.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7399-409 [10523628.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27144-53 [12023274.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4705-12 [12468531.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1896-909 [12612065.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6363-9 [14559825.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7460-74 [14559995.001]
  • [Cites] Hematol J. 2004;5(3):262-72 [15167914.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2841-52 [15215894.001]
  • [Cites] Nature. 1989 Jun 8;339(6224):446-51 [2725678.001]
  • [Cites] Cell. 1989 Sep 8;58(5):877-85 [2776214.001]
  • [Cites] EMBO J. 1990 Sep;9(9):2997-3002 [2118109.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):15180-4 [1907971.001]
  • [Cites] J Biol Chem. 1991 Nov 25;266(33):22159-63 [1939237.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:663-98 [1809356.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6290-303 [8413228.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5597-605 [11067915.001]
  • (PMID = 15967790.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA016368; United States / NHLBI NIH HHS / HL / HL077242-01; United States / NHLBI NIH HHS / HL / HL78381-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / Bcl2l1 protein, mouse; 0 / DNA-Binding Proteins; 0 / Erythroid-Specific DNA-Binding Factors; 0 / G-Box Binding Factors; 0 / GATA1 Transcription Factor; 0 / Gata1 protein, mouse; 0 / Interleukin-3; 0 / Nfil3 protein, mouse; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; 0 / bcl-X Protein; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases
  • [Other-IDs] NLM/ NIHMS327442; NLM/ PMC3193074
  •  go-up   go-down


45. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A: BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest; 2010 Dec 1;120(12):4569-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
  • B cell lymphoma 6 (BCL6), which encodes a transcriptional repressor, is a critical oncogene in diffuse large B cell lymphomas (DLBCLs).
  • Although a retro-inverted BCL6 peptide inhibitor (RI-BPI) was recently shown to potently kill DLBCL cells, the underlying mechanisms remain unclear.
  • Here, we show that RI-BPI induces a particular gene expression signature in human DLBCL cell lines that included genes associated with the actions of histone deacetylase (HDAC) and Hsp90 inhibitors.
  • Induction of p300 and BAT3 was required for the antilymphoma effects of RI-BPI, since specific blockade of either protein rescued human DLBCL cell lines from the BCL6 inhibitor.
  • Furthermore, HDAC and Hsp90 inhibitors independently enhanced RI-BPI killing of primary human DLBCL cells in vitro.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21041953.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA155226; United States / NIGMS NIH HHS / GM / R37 GM062437; United States / NCI NIH HHS / CA / R01-CA104348; United States / NCI NIH HHS / CA / K08 CA127353; United States / NIGMS NIH HHS / GM / GM62437; United States / NIGMS NIH HHS / GM / R01 GM062437; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CA / R01 CA104348; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / R01 CA143032
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAG6 protein, human; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Molecular Chaperones; EC 2.3.1.48 / E1A-Associated p300 Protein; EC 2.3.1.48 / EP300 protein, human
  •  go-up   go-down


46. Yang N, Gong F, Sun L, Yang D, Han X, Ma C, Sun Y: Poly (ADP-ribose) polymerase-1 binds to BCL2 major breakpoint region and regulates BCL2 expression. J Cell Biochem; 2010 Aug 1;110(5):1208-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BCL2, originally identified as a proto-oncogene in B-cell lymphoma, is a key regulator of apoptosis.
  • Although it is more than 200 kb in length, at least 70% of the t(14;18) translocation in follicular lymphomas occurs at the BCL2 major breakpoint region (mbr), located in the 3'-untranslated region (3'-UTR).
  • In this study, we purified Poly(ADP-ribose) polymerase-1 (PARP-1) from the DNA-protein complexes formed by 37 mbr in Jurkat cells and demonstrated that PARP-1 participates in the 37 mbr-protein complex's formation in vitro and in vivo.
  • [MeSH-major] Chromosome Breakpoints. Gene Expression Regulation, Neoplastic. Poly(ADP-ribose) Polymerases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] 3' Untranslated Regions / genetics. Blotting, Western. Cell Line. Cell Line, Tumor. Humans. Jurkat Cells. Protein Binding. RNA Interference. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2010 Wiley-Liss, Inc.
  • (PMID = 20564216.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


47. Andréasson U, Ek S, Merz H, Rosenquist R, Andersen N, Jerkeman M, Dictor M, Borrebaeck CA: B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett; 2008 Feb 8;259(2):138-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.
  • To study the differential expression of cell membrane-bound receptors and their potential role in growth and/or survival of the tumor cells, highly purified follicular lymphoma cells were analyzed, using gene expression analysis, and compared to non-malignant B cell populations.
  • Filtering the genome for overexpressed genes coding for cell membrane-bound proteins/receptors resulted in a hit list of 27 identified genes.
  • Among these, we have focused on the aberrant over expression of CX3CR1, in different types of B cell lymphoma, as compared to non-malignant B cells.
  • We show that CX3CR1, which normally is not expressed on B cells, is expressed both at the mRNA and protein level in several subtypes of lymphoma.
  • CX3CR1 has also shown to be involved in the homing to specific tissues that express the ligand, CX3CL1, in breast and prostate cancer and may thus be involved in dissemination of lymphoma.
  • [MeSH-major] B-Lymphocytes / immunology. Lymphoma, Follicular / immunology. Lymphoma, Mantle-Cell / immunology. Palatine Tonsil / immunology. Receptors, Chemokine / analysis
  • [MeSH-minor] Cell Separation. Flow Cytometry. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060687.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CX3CR1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Chemokine
  •  go-up   go-down


48. Hara T, Omura-Minamisawa M, Chao C, Nakagami Y, Ito M, Inoue T: Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):517-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells.
  • PURPOSE: Bcl-2, an inhibitor of apoptosis frequently shows elevated expression in human tumors, thus resulting in resistance to radiation therapy.
  • Therefore, inhibiting Bcl-2 function may enhance the radiosensitivity of tumor cells.
  • Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively.
  • We investigated whether these antitumor agents would enhance the cytotoxic effects of radiation in tumor cells overexpressing Bcl-2.
  • METHODS AND MATERIALS: We used HeLa/bcl-2 cells, a stable Bcl-2-expressing cell line derived from wild-type HeLa (HeLa/wt) cells.
  • Cells were incubated with TC-A and bcl-2 antisense oligonucleotides for 24 h after irradiation, and cell viability was then determined.
  • Apoptotic cells were quantified by flow cytometric assay.
  • RESULTS: The HeLa/bcl-2 cells were more resistant to radiation than HeLa/wt cells.
  • At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells.
  • However, in HeLa/bcl-2 cells, additional treatment with TC-A in combination with radiation did not significantly increase apoptosis.
  • CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2.
  • Therefore, a combination of radiotherapy and Bcl-2 inhibitors may prove to be a useful therapeutic approach for treating tumors that overexpress Bcl-2.
  • [MeSH-major] Aminoglycosides / pharmacology. Apoptosis. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Analysis of Variance. Cell Survival / drug effects. Cell Survival / radiation effects. HeLa Cells / drug effects. HeLa Cells / metabolism. HeLa Cells / radiation effects. Humans. RNA, Messenger / antagonists & inhibitors. Tumor Stem Cell Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667975.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Radiation-Sensitizing Agents; 73666-84-9 / tetrocarcin A
  •  go-up   go-down


49. Zubor P, Hatok J, Galo S, Dokus K, Klobusiakova D, Danko J, Racay P: Anti-apoptotic and pro-apoptotic gene expression evaluated from eutopic endometrium in the proliferative phase of the menstrual cycle among women with endometriosis and healthy controls. Eur J Obstet Gynecol Reprod Biol; 2009 Aug;145(2):172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hence, we investigated the expression of pro-apoptotic and anti-apoptotic genes in eutopic endometrium from women with endometriosis and healthy controls in relation to disease occurrence and severity.
  • The mRNA expression of apoptotic genes (p53, Bcl-x(L,S) and Bax) from eutopic endometrium was detected by RT-PCR.
  • RESULTS: A significant increase in expression of mRNA p53 (1.42 versus 1.02; p<0.05), and Bcl-x(S) (0.41 versus 0.19; p=0.0006) was found in women with endometriosis compared to healthy controls.
  • The expression of anti-apoptotic Bcl-x(L) was unchanged (1.08 versus 1.07).
  • The Bcl-x(L)/Bcl-x(S) ratio was twofold higher (5.63 versus 2.63) in controls.
  • By stratifying patients by disease stage we have revealed an increased mRNA expression of apoptotic genes in patients with grades III-IV endometriosis compared to those with grades I-II.
  • However, the difference was significant only for Bcl-x(S) expression (p<0.05).
  • CONCLUSIONS: Results suggest that an increased transcription of pro-apoptotic genes (p53 and Bcl-x(S)) in eutopic endometrium is significantly associated with endometriosis, which indicates dysregulation of apoptotic gene transcription associated with disease.
  • [MeSH-major] Apoptosis. Endometriosis / metabolism. Endometrium / metabolism. Follicular Phase / physiology. Infertility, Female / metabolism. Tumor Suppressor Protein p53 / biosynthesis. bcl-2-Associated X Protein / biosynthesis. bcl-X Protein / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467764.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


50. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, Perugini MA, Huang DC, Colman PM: Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ; 2008 Oct;15(10):1564-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
  • Some viruses express proteins homologous in sequence and function to mammalian pro-survival Bcl-2 proteins.
  • Anti-apoptotic F1L expressed by vaccinia virus is essential for survival of infected cells, but it bears no discernable sequence homology to proteins other than its immediate orthologues in related pox viruses.
  • Here we report that the crystal structure of F1L reveals a Bcl-2-like fold with an unusual N-terminal extension.
  • Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins.
  • [MeSH-major] Protein Structure, Quaternary. Protein Structure, Tertiary. Proto-Oncogene Proteins c-bcl-2 / chemistry. Viral Proteins / chemistry. Viral Proteins / metabolism


51. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood; 2008 Oct 1;112(7):2906-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of antiapoptotic members of the Bcl-2 family is observed in approximately 80% of B-cell lymphomas, contributing to intrinsic and acquired drug resistance.
  • ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X(L), and Bcl-w.
  • In vitro, ABT-737 exhibited concentration-dependent cytotoxicity against a broad panel of lymphoma cell lines including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).
  • ABT-737 showed synergism when combined with the proteasome inhibitors bortezomib or carfilzomib in select lymphoma cell lines and induced potent mitochondrial membrane depolarization and apoptosis when combined with either.
  • ABT-737 plus bortezomib also induced significant apoptosis in primary samples of MCL, DLBCL, and chronic lymphocytic leukemia (CLL) but no significant cytotoxic effect was observed in peripheral blood mononuclear cells from healthy donors.
  • Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biphenyl Compounds / pharmacology. Enzyme Inhibitors / pharmacology. Lymphoma / enzymology. Lymphoma / pathology. Molecular Mimicry / drug effects. Nitrophenols / pharmacology. Proteasome Inhibitors. Sulfonamides / pharmacology
  • [MeSH-minor] Animals. Boronic Acids / pharmacology. Bortezomib. Cell Death / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm / drug effects. Drug Synergism. Health. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukocytes, Mononuclear / drug effects. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Mantle-Cell / pathology. Membrane Potential, Mitochondrial / drug effects. Mice. Microscopy, Confocal. Piperazines / pharmacology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazines / pharmacology. Tissue Donors. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591385.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT-737; 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 0 / Boronic Acids; 0 / Enzyme Inhibitors; 0 / Nitrophenols; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 0 / Sulfonamides; 69G8BD63PP / Bortezomib
  •  go-up   go-down


52. Bolisetty MT, Dy G, Tam W, Beemon KL: Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol; 2009 Dec;83(23):12009-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival.
  • The precursor of miR-155, termed bic, was first observed to cooperate with myc in chicken B-cell lymphomas induced by avian leukosis proviral integrations.
  • We also observed very high levels of miR-155 in REV-T-induced B-cell lymphomas.
  • To study the role of miR-155 in these tumors, we identified JARID2/Jumonji, a cell cycle regulator and part of a histone methyltransferase complex, as a target of miR-155.
  • Further, the overexpression of a sponge complementary to miR-155 in a tumor cell line increased endogenous JARID2 mRNA levels.
  • The overexpression of JARID2 in chicken fibroblasts led to decreased cell numbers and an increase in apoptotic cells.
  • The overexpression of miR-155 rescued cells undergoing cytopathic effect caused by infection with subgroup B avian retroviruses.
  • [MeSH-minor] Animals. Cell Line. Cell Survival. Chickens. Fibroblasts / virology. Humans

  • Genetic Alliance. consumer health - Reticuloendotheliosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6925-37 [10602467.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5082-9 [17911593.001]
  • [Cites] J Virol. 2000 Dec;74(24):11490-4 [11090145.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] J Virol. 2002 May;76(9):4275-86 [11932393.001]
  • [Cites] J Virol. 2002 Jun;76(11):5581-7 [11991986.001]
  • [Cites] J Virol. 2003 Sep;77(17):9378-87 [12915553.001]
  • [Cites] J Virol. 2003 Dec;77(23):12552-61 [14610178.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2275-86 [14755244.001]
  • [Cites] J Virol. 2004 May;78(10):5139-46 [15113896.001]
  • [Cites] RNA. 2004 Oct;10(10):1507-17 [15383676.001]
  • [Cites] Virology. 1979 Feb;93(1):20-30 [219596.001]
  • [Cites] Cell. 1981 Aug;25(2):421-31 [6269747.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18952-7 [18024587.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2654-62 [18048365.001]
  • [Cites] RNA Biol. 2007 Nov;4(3):131-7 [18347435.001]
  • [Cites] J Virol. 2008 Jun;82(11):5295-306 [18367535.001]
  • [Cites] Immunity. 2008 May;28(5):621-9 [18450484.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):570-80 [18950466.001]
  • [Cites] J Virol. 2008 Dec;82(24):12213-20 [18842708.001]
  • [Cites] J Virol. 2009 Jan;83(1):489-92 [18945769.001]
  • [Cites] J Biol Chem. 2009 Jan 9;284(2):733-9 [19010785.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):80-91 [19144316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40 [19193853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8 [19359473.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1374-82 [19520806.001]
  • [Cites] J Virol. 1981 Sep;39(3):713-21 [6270346.001]
  • [Cites] Nature. 1984 Feb 23-29;307(5953):702-8 [6321996.001]
  • [Cites] J Virol. 1984 Oct;52(1):172-82 [6090694.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1126-32 [2999973.001]
  • [Cites] J Biol Chem. 1987 Mar 5;262(7):3422-7 [3029112.001]
  • [Cites] J Virol. 1987 Oct;61(10):3004-12 [3041020.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Avian Dis. 1992 Apr-Jun;36(2):432-9 [1320872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1490-502 [9032277.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2997-3009 [9566919.001]
  • [Cites] Trends Cell Biol. 1998 May;8(5):202-6 [9695840.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):4672-83 [10373516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] RNA. 2005 Apr;11(4):459-69 [15703439.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):30916-23 [15870077.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Dev Biol. 2007 Mar 15;303(2):549-60 [17189626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] RNA. 2007 Jun;13(6):930-6 [17456563.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5640-3 [11059754.001]
  • (PMID = 19759154.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124596; United States / NCI NIH HHS / CA / R01 CA124596
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2786729
  •  go-up   go-down


53. Chen AI, Advani RH: Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. J Natl Compr Canc Netw; 2008 Apr;6(4):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
  • Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis.
  • Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL.
  • These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma.
  • These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings.
  • Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Diphtheria Toxin / therapeutic use. Histone Deacetylase Inhibitors. Humans. Immunosuppressive Agents / therapeutic use. Interleukin-2 / therapeutic use. Practice Guidelines as Topic. Protease Inhibitors / therapeutic use. Purine Nucleosides / therapeutic use. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. Pyrimidinones / therapeutic use. Recombinant Fusion Proteins / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433608.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Diphtheria Toxin; 0 / Histone Deacetylase Inhibitors; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Protease Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 0 / Recombinant Fusion Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / zanolimumab; 0W860991D6 / Deoxycytidine; 25E79B5CTM / denileukin diftitox; 3A189DH42V / alemtuzumab; 426X066ELK / forodesine; 60158CV180 / nelarabine; B76N6SBZ8R / gemcitabine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


54. Woroniecka R, Grygalewicz B, Pienkowska-Grela B, Rymkiewicz G, Konecki R, Swoboda P, Janik P: Variant t(2;11)(p11.2;q13) without IGK involvement in a case of mantle cell lymphoma. Cancer Genet Cytogenet; 2007 Jun;175(2):154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant t(2;11)(p11.2;q13) without IGK involvement in a case of mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation, which leads to overexpression of the cyclin D1 (CCND1) gene.
  • Translocations affecting IGH loci are mostly prevalent in B-cell lymphomas, but variant translocations involving immunoglobulin kappa (IGK) or lambda (IGL) light chain loci have been observed in a minority of B-lymphoid malignancies.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 2 / genetics. Genetic Variation. Immunoglobulin kappa-Chains. Lymphoma, Mantle-Cell / genetics. Translocation, Genetic


55. Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, Alkis N: Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma. Exp Oncol; 2006 Dec;28(4):326-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.
  • The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Blood Viscosity. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285120.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


56. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M: [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2059-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
  • To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).
  • The 5-year probability of disease-free survival for patients in the low-risk group and in the high-risk group was 68.8% and 60.0%,respectively (p = 0.9 6).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352929.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


57. Lin P, Jetly R, Lennon PA, Abruzzo LV, Prajapati S, Medeiros LJ: Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature. Hum Pathol; 2008 Nov;39(11):1664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature.
  • Follicular lymphomas characteristically carry t(14;18)(q32;q21) which results in IGH-BCL-2 fusion.
  • Variant translocations that juxtapose the BCL-2 gene with the immunoglobulin kappa (2p11) and lambda (22q11) light chain genes are rare.
  • We report 4 cases of B-cell lymphoma/leukemia associated with t(18;22)(q21;q11).
  • Three cases were classified as chronic lymphocytic leukemia, and one as follicular lymphoma based on morphology and immunophenotype.
  • Fluorescence in situ hybridization analysis was performed on all 4 cases using a BCL-2 breakapart probe.
  • The BCL-2 gene was rearranged in all cases.
  • These cases illustrate that t(18;22)(q21;q11) is more commonly observed in chronic lymphocytic leukemia and may represent either an initial or secondary genetic event.
  • [MeSH-major] Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 22. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Aged. Fatal Outcome. Female. Gene Rearrangement, B-Lymphocyte. Genes, bcl-2. Humans. Male. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656237.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


58. Joseph LD, Panicker VK, Prathiba D, Damodharan J: Subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient. J Assoc Physicians India; 2005 Apr;53:314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient.
  • Immunocompromised patients are at increased risk for developing certain malignant tumors, particularly aggressive B cell lymphomas and extranodal lymphomas like primary central nervous system lymphoma and primary effusion lymphoma.
  • T cell lymphomas are uncommon in these patients.
  • We report a rare case of subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient who presented with multiple subcutaneous nodules.
  • [MeSH-major] CD8-Positive T-Lymphocytes / pathology. HIV Infections / complications. Lymphoma, T-Cell / diagnosis. Panniculitis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / pathology. Adult. Cytoplasm / pathology. Diagnosis, Differential. Humans. Male. Risk Factors


59. Meyer J, Delay J, Bienzle D: Clinical, laboratory, and histopathologic features of equine lymphoma. Vet Pathol; 2006 Nov;43(6):914-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, laboratory, and histopathologic features of equine lymphoma.
  • Clinical, laboratory and tissue findings from 37 horses with lymphoma were investigated.
  • Tumor cell morphology was heterogeneous in 17 tumors, and 8 tumors had marked histiocytic and multinucleated giant cell infiltrates.
  • Extensive necrosis or focal fibrosis was present in 22 and 4 lymphomas, respectively.
  • Staining of tumor sections with antibodies against CD3 and CD79alpha molecules resulted in classification of T-cell (n = 26) or B-cell (n = 7) origin.
  • Most T-cell tumors comprised small to medium CD3(+) lymphocytes, whereas 5 of 7 B-cell tumors were infiltrated by numerous small T lymphocytes and classified as T-cell-rich B-cell lymphoma.
  • Fresh tumor cells from 6 horses bound antibodies reactive with equine CD4, CD5, CD8, CD21, or major histocompatibility class II molecules, confirming T-cell (n = 5) or B-cell origin (n = 1).
  • These findings suggest that T-cell lymphoma is more common than B-cell lymphoma in horses and that inflammation, possibly from tumor cytokine production, is frequent.
  • [MeSH-major] Horse Diseases / pathology. Lymphoma / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099148.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Haddadin WJ: Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med; 2005 Sep-Oct;25(5):398-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification.
  • BACKGROUND: Most studies describing the subtypes of lymphoma in Jordan were carried out in the 1980s at a time when immunohistochemical facilities were unavailable.
  • Using a database established after immunohistochemical studies were introduced, we determined the frequency of the various types of nodal and extranodal lymphomas in the adult and paediatric Jordanian population.
  • We also assessed the incidence of bone marrow involvement at the initial presentation for each lymphoma type.
  • METHODS: A retrospective analysis of the histopathological subtypes of various lymphomas was conducted on all primary lymphoma cases diagnosed during a 3-year period between January 2001 and December 2003.
  • RESULTS: Of 347 patients included in the study, 78.4% had non-Hodgkin's lymphoma (NHL) and 21.6% had Hodgkin's lymphoma (HL).
  • In the NHL group, diffuse large B-cell lymphoma was the most common (28.2%) followed by follicular lymphoma (15.6%).
  • In the HL group, the nodular sclerosis variant was the most frequent (7.8%) followed by the mixed cellularity type (5.5%).
  • Of all the lymphoma cases, the highest incidence of marrow involvement was seen in patients with lymphoplasmacytic lymphoma.
  • Forty-nine patients were children (age <15 years) in whom Burkitt's lymphoma (15 cases) and HL (14 cases) were the commonest subtypes.
  • One-hundred six patients with primary extranodal lymphomas (ENL) accounted for 30.5% of all lymphomas.
  • Among the various lymphomas, diffuse large B-cell lymphoma is the most commonly encountered lymphoma in adults.
  • Burkitt's lymphoma and Hodgkin's disease are the most frequent childhood lymphomas, followed closely by lymphoblastic lymphoma.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270763.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


61. Westphal D, Ledgerwood EC, Hibma MH, Fleming SB, Whelan EM, Mercer AA: A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus. J Virol; 2007 Jul;81(13):7178-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.
  • Apoptotic cell death forms part of the host defense against virus infection.
  • We tested orf virus, a member of the poxvirus family, for the ability to inhibit apoptosis and found that orf virus-infected cells were fully resistant to UV-induced changes in cell morphology, caspase activation, and DNA fragmentation.
  • These features are comparable to the antiapoptotic properties of the mitochondrial regulator Bcl-2.
  • Furthermore, bioinformatic analyses revealed sequence and secondary-structure similarities to Bcl-2 family members, including characteristic residues of all four Bcl-2 homology domains.
  • Consistent with this, the viral protein inhibited the UV-induced activation of the proapoptotic Bcl-2 family members Bax and Bak.
  • ORFV125 is the first parapoxvirus apoptosis inhibitor to be identified, and we propose that it is a new antiapoptotic member of the Bcl-2 family.
  • [MeSH-minor] Apoptosis. Caspases / metabolism. DNA Fragmentation / radiation effects. Enzyme Activation / genetics. Enzyme Activation / radiation effects. HeLa Cells. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Mitochondria / metabolism. Protein Structure, Secondary. Protein Structure, Tertiary. Ultraviolet Rays. bcl-2 Homologous Antagonist-Killer Protein / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 May 15;60(10):2666-72 [10825139.001]
  • [Cites] J Virol. 2004 Jan;78(1):353-66 [14671117.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2803-11 [11038395.001]
  • [Cites] Protein Sci. 2000 Dec;9(12):2528-34 [11206074.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7 [11248023.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1615-25 [12006657.001]
  • [Cites] Curr Opin Microbiol. 2002 Aug;5(4):395-402 [12160859.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] J Gen Virol. 2000 Apr;81(Pt 4):1087-97 [10725436.001]
  • [Cites] J Virol. 2000 Apr;74(8):3815-31 [10729156.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1487-98 [10790424.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):95-105 [14996494.001]
  • [Cites] J Virol. 2004 Jul;78(13):7097-111 [15194786.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Arch Virol. 1982;71(1):43-55 [6279055.001]
  • [Cites] Nucleic Acids Res. 1987 Sep 11;15(17):7192 [2821498.001]
  • [Cites] Arch Virol. 1988;101(3-4):255-9 [3178493.001]
  • [Cites] J Virol. 1994 Dec;68(12):7728-37 [7966562.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):405-14 [9053837.001]
  • [Cites] Virology. 1997 Mar 3;229(1):193-200 [9123861.001]
  • [Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):95-9 [9405280.001]
  • [Cites] Virology. 1998 May 10;244(2):365-96 [9601507.001]
  • [Cites] Virus Genes. 1998;17(2):107-15 [9857983.001]
  • [Cites] Trends Microbiol. 1999 Apr;7(4):160-5 [10217831.001]
  • [Cites] Curr Opin Cell Biol. 2004 Dec;16(6):647-52 [15530776.001]
  • [Cites] J Virol. 2005 Jan;79(2):1084-98 [15613337.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):951-60 [15531603.001]
  • [Cites] Cancer Biol Ther. 2005 Feb;4(2):139-63 [15725726.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):83-9 [15727562.001]
  • [Cites] FEBS Lett. 2005 Jul 4;579(17):3503-7 [15949801.001]
  • [Cites] J Virol. 2005 Nov;79(22):14031-43 [16254338.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):617-25 [16243507.001]
  • [Cites] J Virol. 2006 Feb;80(3):1140-51 [16414991.001]
  • [Cites] Virus Res. 2006 Mar;116(1-2):146-58 [16274827.001]
  • [Cites] Cell Death Differ. 2006 Sep;13(9):1423-33 [16676004.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1651-62 [16439990.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39728-39 [17074758.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):933-42 [17386268.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2286-95 [10822379.001]
  • [Cites] J Cell Biol. 2003 Jan 6;160(1):53-64 [12515824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2432-7 [12591950.001]
  • [Cites] Cell Death Differ. 2003 Jan;10 Suppl 1:S68-76 [12655348.001]
  • [Cites] EMBO J. 2003 Apr 1;22(7):1497-507 [12660157.001]
  • [Cites] Bioessays. 2003 Sep;25(9):888-96 [12938178.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):877-87 [12952938.001]
  • [Cites] Immunity. 2003 Sep;19(3):341-52 [14499110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14345-50 [14610284.001]
  • [Cites] J Virol. 2004 Jan;78(1):168-77 [14671098.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • (PMID = 17475653.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / Viral Proteins; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1933275
  •  go-up   go-down


62. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol; 2005 Feb 1;23(4):712-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
  • PURPOSE: To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and overall survival and safety with the tositumomab and iodine-131 tositumomab ((131)I tositumomab) therapeutic regimen in patients with indolent, follicular large-cell, or transformed B-cell lymphoma, progressive after rituximab.
  • CONCLUSION: (131)I tositumomab is effective in CD20-positive lymphoma progressive after rituximab, with a 65% OR rate and median PFS of 24.5 months for responders.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613695.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


63. Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL, Carbone A: Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol; 2008 Aug;49(2):170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas.
  • BACKGROUND/AIMS: The gastrointestinal tract is the most common site of mucosa-associated lymphoid tissue (MALT) lymphoma development.
  • Among the several genetic abnormalities involved in MALT development, the impact of t(14;18)-(IgH;Bcl-2) translocation has only been marginally analyzed.
  • To this end, a consecutive series of gastrointestinal MALT lymphomas were analyzed.
  • METHODS: t(14;18)-(IgH;Bcl-2) translocation, at the major break point region (MBR) and minor cluster region (mcr), were assessed by the polymerase chain reaction (PCR) in tumour DNA obtained from 40 consecutive gastrointestinal MALT lymphoma patients.
  • Interestingly, both lymphomas bearing t(14;18) translocation derived from patients with chronic HCV infection.
  • Nucleotide sequence analysis confirmed that Bcl-2 was joined to JH6 in both MALT lymphomas.
  • Moreover, the heavy chain gene combinations detected in both MALT lymphomas were those usually found in the HCV-associated lymphomas.
  • CONCLUSIONS: Our data support the notion that among gastrointestinal MALT lymphomas, t(14;18)-(IgH;Bcl-2) translocation clusters in HCV-positive patients sustaining the role of HCV infection in the lymphoma development.
  • [MeSH-major] Gastrointestinal Neoplasms / genetics. Genes, bcl-2 / genetics. Hepatitis C / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell, Marginal Zone / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538438.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


64. Boffetta P, van der Hel O, Kricker A, Nieters A, de Sanjosé S, Maynadié M, Cocco PL, Staines A, Becker N, Font R, Mannetje A', Goumas C, Brennan P: Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study. Int J Epidemiol; 2008 Oct;37(5):1080-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study.
  • BACKGROUND: Three recent studies have reported a decreased risk of non-Hodgkin lymphoma (NHL) for high ultraviolet (UV) radiation exposure.
  • METHODS: We conducted a multicentre case-control study during 1998-2004 in France, Germany, Ireland, Italy and Spain, comprising 1518 cases of NHL, 268 cases of Hodgkin lymphoma, 242 cases of multiple myeloma and 2124 population or hospital controls.
  • RESULTS: The risk of Hodgkin and NHL was increased for increasing skin sensitivity to the sun [odds ratio (OR) for no suntan vs very brown 2.35, 95% CI 0.94-5.87 and 1.39, 95% CI 1.03-1.87, respectively].
  • The risk of diffuse large B-cell lymphoma was reduced for increasing adult personal (OR for highest vs lowest quartile of exposure in free days 0.62, 95% CI 0.44-0.87) and for occupational exposure to UV radiation (OR for highest vs lowest exposure tertile 0.63, 95% CI 0.37-1.04).
  • A protective effect was observed for use of sun lamps for diffuse large B-cell lymphoma (OR for 25+ times vs never 0.63, 95% CI 0.38-1.03).
  • CONCLUSIONS: The hypothesis of a protective effect of UV radiation on lymphoma is supported by our results.
  • [MeSH-major] Lymphoma / etiology. Multiple Myeloma / etiology. Neoplasms, Radiation-Induced. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adult. Case-Control Studies. Europe. European Continental Ancestry Group. Hodgkin Disease / etiology. Humans. Lymphoma, Large B-Cell, Diffuse / prevention & control. Lymphoma, Non-Hodgkin / etiology. Occupational Exposure. Odds Ratio. Risk. Skin Pigmentation. Sunburn / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511490.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell; 2005 Feb 04;17(3):393-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
  • Apoptosis is initiated when Bcl-2 and its prosurvival relatives are engaged by proapoptotic BH3-only proteins via interaction of its BH3 domain with a groove on the Bcl-2-like proteins.
  • These interactions have been considered promiscuous, but our analysis of the affinity of eight BH3 peptides for five Bcl-2-like proteins has revealed that the interactions vary over 10,000-fold in affinity, and accordingly, only certain protein pairs associate inside cells.
  • Bad, however, bound tightly to Bcl-2, Bcl-xL, and Bcl-w but only weakly to A1 and not to Mcl-1.
  • [MeSH-major] Apoptosis / physiology. Cell Survival / physiology. Peptide Fragments / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Apoptosis Regulatory Proteins. Bcl-2-Like Protein 11. Binding, Competitive. Biosensing Techniques. Carrier Proteins / chemistry. Carrier Proteins / genetics. Carrier Proteins / metabolism. Genetic Complementation Test. Humans. In Vitro Techniques. Ligands. Membrane Proteins / chemistry. Membrane Proteins / genetics. Membrane Proteins / metabolism. Mice. Models, Biological. Models, Molecular. Molecular Sequence Data. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Proteins / chemistry. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Protein Structure, Tertiary. Proteins / chemistry. Proteins / genetics. Proteins / metabolism. Recombinant Proteins / chemistry. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Sequence Homology, Amino Acid. bcl-X Protein


66. Sansonno D, Tucci FA, Lauletta G, De Re V, Montrone M, Troiani L, Sansonno L, Dammacco F: Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Exp Immunol; 2007 Feb;147(2):241-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia.
  • HCV minus strand RNA, the viral replicative intermediate, was searched for by a polyA(+) tract strand-specific Tth-based reverse transcriptase-polymerase chain reaction (RT-PCR) in lymphoid cells of 46 patients with acute and chronic infection.
  • The HCV replicating form in lymphoid cells was associated strictly with mixed cryoglobulinaemia (MCG), in that it was found in six of 13 (46%) MCG patients, including two with B cell non-Hodgkin's lymphoma (NHL).
  • These results emphasize the direct role of the virus in the pathogenesis of MCG and support the contention that HCV is not specifically lymphotropic, its entry and replication in lymphoid cells being determined largely by selective interactions.
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / virology. Female. Hepatitis C, Chronic / complications. Humans. Lymphoma, B-Cell / virology. Male. Middle Aged. RNA, Viral / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Virus Replication

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Viral Hepat. 2004 Jul;11(4):310-8 [15230853.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;242:55-84 [10592656.001]
  • [Cites] Arch Virol. 1994;134(3-4):293-302 [7510473.001]
  • [Cites] Virology. 1994 Aug 1;202(2):606-14 [8030225.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1887-92 [7655017.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] J Virol. 1995 Dec;69(12):8079-83 [7494326.001]
  • [Cites] Clin Exp Immunol. 1996 Mar;103(3):414-21 [8608640.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):845-51 [8609243.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3328-37 [9787170.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):491-8 [15763335.001]
  • [Cites] Science. 2005 Jul 22;309(5734):623-6 [15947137.001]
  • [Cites] J Virol. 2000 May;74(10):4824-30 [10775621.001]
  • [Cites] Hepatology. 2000 Aug;32(2):382-7 [10915746.001]
  • [Cites] Adv Virus Res. 2000;55:231-69 [11050944.001]
  • [Cites] Eur J Clin Invest. 2001 Jul;31(7):628-38 [11454019.001]
  • [Cites] Cell. 2002 Mar 8;108(5):717-25 [11893341.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5017-25 [12356718.001]
  • [Cites] Blood. 2003 Jan 1;101(1):52-7 [12393733.001]
  • [Cites] J Virol. 2003 Mar;77(5):3007-19 [12584326.001]
  • [Cites] J Exp Med. 2003 Mar 3;197(5):633-42 [12615904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6 [12761383.001]
  • [Cites] J Virol. 2003 Oct;77(19):10432-6 [12970428.001]
  • [Cites] Eur J Immunol. 2004 Jan;34(1):126-36 [14971038.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1019-27 [16231354.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):436-9 [16360233.001]
  • [Cites] J Virol. 2006 Feb;80(4):1734-41 [16439530.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1107-16 [16618405.001]
  • [Cites] Clin Exp Immunol. 2006 Feb;143(2):288-96 [16412053.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71 [10535997.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5 [1848704.001]
  • (PMID = 17223964.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC1810461
  •  go-up   go-down


67. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y: Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res; 2008 Apr 1;68(7):2400-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest.
  • Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa.
  • TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs.
  • Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)(4)-Fc and C2B8(ScFvHL)(4)-Fc, were significantly different.
  • Immunotherapeutic studies further showed that 2F2(ScFvHL)(4)-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)(4)-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Antineoplastic Agents / pharmacology. Burkitt Lymphoma / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Mice, SCID. Rituximab. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381448.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD30; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


68. Ci W, Polo JM, Melnick A: B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr Opin Hematol; 2008 Jul;15(4):381-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
  • PURPOSE OF REVIEW: The B-cell lymphoma 6 transcriptional repressor is the most commonly involved oncogene in B-cell lymphomas.
  • Sustained expression of B-cell lymphoma 6 causes malignant transformation of germinal center B cells.
  • Understanding the mechanism of action of B-cell lymphoma 6 is crucial for the study of how aberrant transcriptional programming leads to lymphomagenesis and development of targeted antilymphoma therapy.
  • RECENT FINDINGS: Identification of B-cell lymphoma 6 target genes indicates a critical role for B-cell lymphoma 6 in facilitating a state of physiological genomic instability required for germinal center B cells to undergo affinity maturation, and suggests its contribution to several additional cellular functions.
  • The discovery of several layers of counterregulatory mechanisms reveals how B cells can control and fine-tune the potentially lymphomagenic actions of B-cell lymphoma 6.
  • From the biochemical standpoint, B-cell lymphoma 6 can regulate distinct biological pathways through different cofactors.
  • This observation explains how the biological actions of B-cell lymphoma 6 can be physiologically controlled through separate mechanisms and affords the means for improved therapeutic targeting.
  • The fact that patients with B-cell lymphoma 6-dependent lymphoma can be identified on the basis of gene signatures suggests that therapeutic trials of B-cell lymphoma 6 inhibitors could be personalized to these individuals.
  • SUMMARY: B-cell lymphoma 6 plays a fundamental role in lymphomagenesis and is an excellent therapeutic target for development of improved antilymphoma therapeutic regimens.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jul-Aug;41(1):95-9 [18346918.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):205-14 [15611242.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Mol Immunol. 2006 May;43(12):1965-71 [16423395.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2223-33 [16331266.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6880-9 [16943429.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Invest. 2000;18(4):356-65 [10808372.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]
  • [Cites] J Exp Med. 2000 Dec 18;192(12):1841-8 [11120780.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):214-20 [10973278.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1551-64 [14690607.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1454-63 [14551142.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] Cell. 2004 Oct 1;119(1):75-86 [15454082.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14198-203 [15375218.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5257-68 [8652841.001]
  • [Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Nature. 2007 Mar 1;446(7131):83-7 [17268470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):819-30 [17403935.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):820-34 [17296600.001]
  • [Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5439-49 [17694085.001]
  • [Cites] J Pathol. 2007 Sep;213(1):106-15 [17573669.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2067-74 [17545502.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):280-92 [17785208.001]
  • [Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]
  • [Cites] Eur J Cell Biol. 2007 Oct;86(10):581-9 [17651861.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1515-23 [17951530.001]
  • [Cites] J Pathol. 2008 Mar;214(4):498-507 [18189332.001]
  • [Cites] Nature. 2008 Feb 14;451(7180):841-5 [18273020.001]
  • [Cites] Mol Cell. 2008 Feb 15;29(3):384-91 [18280243.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2175-86 [18212045.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3361-9 [18451163.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):874-82 [18452090.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4088-96 [15331443.001]
  • (PMID = 18536578.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104348-05; United States / NCI NIH HHS / CA / R01 CA104348; United States / NCI NIH HHS / CA / R01 CA104348-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6
  • [Number-of-references] 51
  • [Other-IDs] NLM/ NIHMS126312; NLM/ PMC2748732
  •  go-up   go-down


69. Sandrini S, Valerio F, Insalaco M: [Kidney transplantation and lymphomas]. G Ital Nefrol; 2010 Sep-Oct;27 Suppl 50:S46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kidney transplantation and lymphomas].
  • [Transliterated title] Linfomi nel trapianto renale.
  • Post-transplant lymphoproliferative disease (PTLD) accounts for 30% of nonskin cancers after kidney transplants.
  • Diffuse large B-cell lymphoma is the most frequent form of PTLD.
  • Moreover, not only is it more frequent but also more serious than the early type because of the lower responsiveness to therapy.
  • Epstein-Barr virus (EVB) infection is one of the most important risk factors for this disease, along with the use of antilymphocyte agents, which should be avoided in EVB-negative patients.
  • During the first year after transplant, EBV-PCR monitoring can be helpful for the early diagnosis of EBV-associated PTLD, especially in children.
  • Chemotherapy becomes essential in relapsed or refractory disease, but it significantly increases the risk of life-threatening infections.
  • The mortality rate is around 50% 12 months after diagnosis, often due to the side effects of chemotherapy.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922695.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


70. Dyer MJ, Akasaka T, Capasso M, Dusanjh P, Lee YF, Karran EL, Nagel I, Vater I, Cario G, Siebert R: Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? Blood; 2010 Feb 25;115(8):1490-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?
  • Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus define common subgroups of B-cell lymphoma but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
  • Recent fluorescent in situ hybridization and molecular cloning studies have identified several novel IGH translocations involving genes that play important roles in normal hemopoiesis, including the cytokine receptor genes CRLF2 and EPOR, all members of the CCAAT enhancer-binding protein gene family, as well as genes not normally expressed in hemopoietic cells including inhibitor of DNA binding 4.
  • The possible clinical importance of many of the various IGH translocations in BCP-ALL remains to be determined from prospective studies, but CRLF2 expression is associated with a poor prognosis.
  • Despite their rarity, IGH chromosomal translocations in BCP-ALL therefore define not only new mechanisms of B-cell transformation but also clinically important subgroups of disease and suggest new targeted therapeutic approaches.
  • [MeSH-major] B-Lymphocytes / metabolism. Cell Transformation, Neoplastic / metabolism. Immunoglobulin Heavy Chains / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Quantitative Trait Loci. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Animals. Core Binding Factor Alpha 2 Subunit / biosynthesis. Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Leukemic / genetics. Hematopoiesis / genetics. Humans. Inhibitor of Differentiation Proteins / biosynthesis. Inhibitor of Differentiation Proteins / genetics. Oncogene Proteins, Fusion / biosynthesis. Oncogene Proteins, Fusion / genetics. Prognosis. Receptors, Cytokine / biosynthesis. Receptors, Cytokine / genetics. Receptors, Erythropoietin / biosynthesis. Receptors, Erythropoietin / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20042721.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRLF2 protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / ID4 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Inhibitor of Differentiation Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Cytokine; 0 / Receptors, Erythropoietin; 0 / TEL-AML1 fusion protein
  • [Number-of-references] 87
  •  go-up   go-down


71. Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T: The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur J Haematol; 2010 Jan 1;84(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
  • EGLN3 also has pro-apoptotic activity in some cell types.
  • Analyses of a well-characterised series of cases of plasma cell dyscrasias, including multiple myeloma (MM), Waldenström's macroglobulinaemia (WM) and monoclonal gammopathy of undetermined significance (MGUS) surprisingly demonstrated that the CpG island of EGLN3, and not EGLN1, is frequently methylated in these disorders.
  • Multiple myeloma patients with a methylated EGLN3 promoter showed trends towards an increased risk of death, bone lytic lesions, anaemia, advanced stage of disease and the presence of extramedullary disease.
  • These data suggest that the prolyl-hydroxylases may be a novel class of potential tumour suppressors in plasma cell neoplasia that warrant further investigation with regard to their potential utility as biomarkers.
  • Moreover, we observed that EGLN3 is also methylated at high frequency in B-cell lymphoma subtypes, implying that loss of EGLN3 is an important epigenetic event not only in plasma cell neoplasias but also in B-cell neoplasias.
  • [MeSH-minor] Aged. Cell Line, Tumor / enzymology. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Hypoxia-Inducible Factor-Proline Dioxygenases. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / genetics. Male. Middle Aged. Monoclonal Gammopathy of Undetermined Significance / enzymology. Monoclonal Gammopathy of Undetermined Significance / genetics. Multiple Myeloma / complications. Multiple Myeloma / enzymology. Multiple Myeloma / genetics. Multiple Myeloma / mortality. Waldenstrom Macroglobulinemia / enzymology. Waldenstrom Macroglobulinemia / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737309.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.13.11.- / Dioxygenases; EC 1.14.11.2 / EGLN1 protein, human; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; EC 1.14.11.29 / EGLN3 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases
  •  go-up   go-down


72. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD: Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol; 2007 Nov;139(3):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
  • Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD).
  • Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases).
  • Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Purine Nucleotides / adverse effects. Risk Factors. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910629.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 113408; United States / NCI NIH HHS / CA / CA 94919; United States / NCI NIH HHS / CA / CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Purine Nucleotides; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


73. McCaw DL, Chan AS, Stegner AL, Mooney B, Bryan JN, Turnquist SE, Henry CJ, Alexander H, Alexander S: Proteomics of canine lymphoma identifies potential cancer-specific protein markers. Clin Cancer Res; 2007 Apr 15;13(8):2496-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomics of canine lymphoma identifies potential cancer-specific protein markers.
  • PURPOSE: Early diagnosis of cancer is crucial for the success of treatment of the disease, and there is a need for markers whose differential expression between disease and normal tissue could be used as a diagnostic tool.
  • Lymphoma, one of the most common neoplasms in dogs, is similar to human non-Hodgkin's lymphoma and could serve as an experimental model system.
  • EXPERIMENTAL DESIGN: Thirteen lymph nodes from normal dogs and 11 lymph nodes from dogs with B-cell lymphoma were subjected to proteomic analysis using two-dimensional PAGE separation and matrix-assisted laser desorption/ionization time-of-flight analysis.
  • Of these, prolidase (proline dipeptidase), triosephosphate isomerase, and glutathione S-transferase were down-regulated in lymphoma samples, whereas macrophage capping protein was up-regulated in the lymphoma samples.
  • CONCLUSIONS: These proteins represent potential markers for the diagnosis of lymphoma and should be further investigated in human samples for validation of their utility as diagnostic markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Dog Diseases / pathology. Lymphoma / veterinary. Neoplasm Proteins / analysis. Proteomics

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438110.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM53929
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


74. Kurkus J, Nilsson R, Lindén O, Schönström N, Sandberg BE, Tennvall J: Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood. Artif Organs; 2007 Mar;31(3):208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of monoclonal antibodies (MAbs) in cytotoxic conjugates (radionuclides, toxins, or drugs) for targeting tumor cells is restricted due to toxicity in vital organs.
  • Through improved tumor targeting, it is possible to administer larger amounts of such labeled MAbs, thus improving the ability to eradicate tumor cells without increased normal organ toxicity.
  • During ECAT, excess radioimmunoconjugates, not bound to the tumor cells, can be removed improving tumor targeting.
  • Seven patients with B-cell lymphoma not responding to conventional treatment were studied.
  • The AA adsorbent had no effect on the blood cells, immunological status or P-bradykinin level.
  • [MeSH-major] Avidin / therapeutic use. Extracorporeal Circulation / instrumentation. Hemoperfusion / methods. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Sepharose / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343696.001).
  • [ISSN] 0160-564X
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / avidin-agarose; 1405-69-2 / Avidin; 9012-36-6 / Sepharose
  •  go-up   go-down


75. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, Pedrinis E, Cavalli F, Pinotti G, Zucca E: Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol; 2009 Jun;20(6):1086-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.
  • BACKGROUND: Treatment aimed at eradicating Helicobacter pylori infection results in lymphoma remission in most localized gastric mucosa-associated lymphoid tissue (MALT) lymphomas.
  • METHODS: One hundred and five patients with localized gastric MALT lymphoma were initially treated only with H. pylori eradication regimens.
  • Lymphoma responses were graded using the Wotherspoon score.
  • Histological regression of the lymphoma was achieved in 78 of 102 assessable patients [76%, 95% confidence interval (CI): 67% to 84%] with complete remission (score 0-2) in 66 and partial remission (score 3) in 12.
  • At a median follow-up time of 6.3 years, histological remission was consistently confirmed in 33 of 74 assessable patients, while 25 had score fluctuations (from 0 to 4) and 13 presented a lymphoma relapse (score 5).
  • Transformation to a large-cell lymphoma was seen in two cases.
  • Only one patient died of lymphoma after transformation to a high-grade lymphoma.
  • CONCLUSIONS: Helicobacter pylori eradication resulted in complete lymphoma remission in the majority of cases.
  • Long-term clinical disease control was achieved in most patients.
  • A watch and wait policy appears to be safe in patients with minimal residual disease or histological-only local relapse.


76. Nemet AY, Deckel Y, Kourt G: Orbital invasion of frontal sinus lymphoma. Orbit; 2006 Jun;25(2):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion of frontal sinus lymphoma.
  • Paranasal sinus lymphoma is an uncommon malignancy and is often difficult to diagnose.
  • Early diagnosis is essential for effective treatment.
  • Ophthalmological symptoms and signs occur early in the disease process due to the close proximity of the orbit to the paranasal sinuses.
  • We report a case of frontal sinus lymphoma that presented as a superior-nasal orbital mass in an 84 year old man.
  • Histology revealed diffuse large B cell non Hodgkin's lymphoma.
  • [MeSH-major] Frontal Sinus / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Orbit / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754228.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Kim SK, Chan CC, Wallace DJ: Management of primary intraocular lymphoma. Curr Oncol Rep; 2005 Jan;7(1):74-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary intraocular lymphoma.
  • Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head.
  • It is usually a large B-cell non-Hodgkin's lymphoma.
  • Diagnosis of PIOL requires pathologic confirmation of malignant cells in specimens of the cerebrospinal fluid, vitreous, or chorioretinal biopsies.
  • However, several new developments for PIOL with central nervous system involvement have been reported, including intrathecal therapy and autologous stem-cell transplantation.
  • In addition, intravitreal methotrexate has been successful in the treatment of isolated recurrent ocular disease.
  • [MeSH-major] Eye Neoplasms / diagnosis. Eye Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Medical Oncology / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy / methods. Humans. Methotrexate / therapeutic use. Radiotherapy / methods. Recurrence. Retina / pathology. Stem Cell Transplantation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):426-7 [11237883.001]
  • [Cites] Oncology (Williston Park). 2000 Feb;14(2):228-34; discussion 237-42, 244 [10736810.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Haematologica. 2004 Jun;89(6):753-4 [15194546.001]
  • [Cites] Cancer. 1989 May 15;63(10):1918-21 [2702565.001]
  • [Cites] Onkologie. 2003 Aug;26(4):351-4 [12972702.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1329 [10561199.001]
  • [Cites] Retina. 2002 Feb;22(1):37-43 [11884876.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 [380030.001]
  • [Cites] Ophthalmology. 1987 Dec;94(12):1631-9 [3323986.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] Arch Ophthalmol. 2001 Oct;119(10):1518-24 [11594954.001]
  • [Cites] Eye (Lond). 2003 May;17(4):513-21 [12802353.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1709-16 [12208721.001]
  • [Cites] Br J Ophthalmol. 1999 Apr;83(4):448-51 [10434868.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Retina. 1995;15(2):125-9 [7624599.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):688-92 [6766795.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):663-73 [7558957.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):137-42 [11307054.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):22-9 [12837150.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Am J Ophthalmol. 1996 Apr;121(4):442-4 [8604740.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1273-5 [2418934.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):531-8 [12056702.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5235-41 [14638722.001]
  • [Cites] Ophthalmology. 2003 Jun;110(6):1241-4 [12799254.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • (PMID = 15610690.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 51
  •  go-up   go-down


78. Walls KC, Ghosh AP, Ballestas ME, Klocke BJ, Roth KA: bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death. J Neuropathol Exp Neurol; 2009 Dec;68(12):1326-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death.
  • In addition to producing neuron death, HI causes death of neural precursor cells (NPCs) in the developing brain.
  • To characterize the molecular pathways that regulate hypoxia-induced death of NPCs, we treated a mouse neural stem cell line (C17.2 cells) and fibroblastic growth factor II-expanded primary NPCs derived from wild-type or gene-disrupted mice, with oxygen glucose deprivation or the hypoxia mimetics desferrioxamine or cobalt chloride.
  • Neural precursor cells undergoing hypoxia exhibited time- and concentration-dependent caspase-3 activation and cell death, which was significantly reduced by treatment with a broad caspase inhibitor or protein synthesis inhibition.
  • Oxygen glucose deprivation or hypoxia-mimetic exposure also resulted in increased hypoxia-inducible factor alpha and bcl-2/adenovirus E1B 19-kd interacting protein 3 (BNIP3) expression.
  • BNIP3 shRNA treatment failed to affect hypoxia-induced caspase-3 activation but inhibited cell death and nuclear translocation of apoptosis-inducing factor, indicating that BNIP3 is an important regulator of caspase-independent NPC death after hypoxia.
  • These studies demonstrate that hypoxia activates both caspase-dependent and -independent NPC death pathways that are critically regulated by multiple Bcl-2 family members.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32631-7 [10551817.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2025-31 [18790835.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5454-68 [10891486.001]
  • [Cites] FEBS Lett. 2001 Feb 23;491(1-2):85-90 [11226425.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] EMBO Rep. 2001 Jul;2(7):615-20 [11454738.001]
  • [Cites] Cell. 2001 Oct 5;107(1):43-54 [11595184.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):189-203 [14996503.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4286-93 [15205343.001]
  • [Cites] Anat Embryol (Berl). 1990;181(3):195-213 [2186664.001]
  • [Cites] Cell. 1992 Jan 10;68(1):33-51 [1732063.001]
  • [Cites] Science. 1995 Oct 6;270(5233):96-9 [7569956.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):405-8 [9537326.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):7-10 [9867803.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):597-609 [15607964.001]
  • [Cites] Neuroscience. 2005;131(1):55-65 [15680691.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):980-91 [15592527.001]
  • [Cites] FASEB J. 2005 Aug;19(10):1308-10 [15941769.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Apoptosis. 2006 Jan;11(1):67-77 [16374551.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1727-39 [16514420.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jan;66(1):66-74 [17204938.001]
  • [Cites] Cell Death Differ. 2007 Apr;14(4):775-84 [17039248.001]
  • [Cites] Cell Biochem Biophys. 2007;47(1):11-20 [17406056.001]
  • [Cites] Stroke. 2007 May;38(5):1606-13 [17379825.001]
  • [Cites] Free Radic Biol Med. 2007 Jul 1;43(1):117-27 [17561100.001]
  • [Cites] Biochem J. 2007 Aug 1;405(3):407-15 [17447897.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1741-8 [17635954.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17):6229-42 [17576813.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2825-33 [17909626.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):616-9 [17786027.001]
  • [Cites] J Neurochem. 2007 Nov;103(3):1121-31 [17711427.001]
  • [Cites] Autophagy. 2008 Feb;4(2):195-204 [18059169.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10892-903 [18281291.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2662-75 [18375543.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1439-48 [10625696.001]
  • (PMID = 19915483.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS047466; United States / NINDS NIH HHS / NS / NS047466-05; United States / NINDS NIH HHS / NS / R01 NS035107-11; United States / NINDS NIH HHS / NS / R01 NS041962; United States / NINDS NIH HHS / NS / P30 NS057098; United States / NINDS NIH HHS / NS / P30 NS047466-05; United States / NINDS NIH HHS / NS / R01 NS041962-06; United States / NINDS NIH HHS / NS / NS57098; United States / NINDS NIH HHS / NS / R01 NS035107; United States / NINDS NIH HHS / NS / NS057098-04; United States / NINDS NIH HHS / NS / NS35107; United States / NINDS NIH HHS / NS / NS035107-11; United States / NINDS NIH HHS / NS / NS47466; United States / NINDS NIH HHS / NS / NS41962; United States / NINDS NIH HHS / NS / NS041962-06; United States / NINDS NIH HHS / NS / P30 NS057098-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNip3 protein, mouse; 0 / Enzyme Inhibitors; 0 / Membrane Proteins; 0 / Mitochondrial Proteins; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS161285; NLM/ PMC2791349
  •  go-up   go-down


79. Henrich M, Hecht W, Weiss AT, Reinacher M: A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of clonality in feline B-cell lymphomas. Vet Immunol Immunopathol; 2009 Jul 15;130(1-2):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of clonality in feline B-cell lymphomas.
  • In human medicine, PCR-amplification of the complementarity determining region 3 of the immunoglobulin heavy chain genes followed by polyacrylamide gel electrophoresis (PAGE) is an accepted method to assess clonality in B-cell lymphomas and thereby facilitates the differentiation of neoplasias from benign hyperplasias or reactive infiltrates.
  • To generate a basis for the development of a PCR-based assay for the assessment of clonality in feline B-cell lymphomas we analyzed 28 transcripts (cDNA) of the feline immunoglobulin heavy chain variable region genes (IGHV).
  • With these four sets of primers, the assay was able to detect monoclonality in 7/10 (70%) cats with histologically and immunohistochemically diagnosed B-cell lymphomas.
  • The use of a PCR-based assay in combination with standard techniques for the diagnosis of feline lymphoma is helpful and the characterization of the additional subgroup of feline variable regions genes puts this assay on a broader basis.
  • [MeSH-major] Cat Diseases / immunology. Cat Diseases / pathology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, B-Cell / veterinary
  • [MeSH-minor] Amino Acid Sequence. Animals. Cats. Clone Cells. Molecular Sequence Data. Plasmids / genetics. RNA, Neoplasm / chemistry. RNA, Neoplasm / genetics. Random Amplified Polymorphic DNA Technique / veterinary. Sequence Alignment. Sequence Analysis, DNA

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243841.001).
  • [ISSN] 1873-2534
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / RNA, Neoplasm
  •  go-up   go-down


80. Ye BS, Sunwoo IN, Suh BC, Park JP, Shim DS, Kim SM: Diffuse large B-cell lymphoma presenting as piriformis syndrome. Muscle Nerve; 2010 Mar;41(3):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma presenting as piriformis syndrome.
  • A diagnosis of diffuse large B-cell lymphoma with neurolymphomatosis (NL) was made.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Piriformis Muscle Syndrome / etiology. Sciatica / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Neural Conduction / physiology. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Piriformis syndrome.
  • MedlinePlus Health Information. consumer health - Sciatica.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19918770.001).
  • [ISSN] 1097-4598
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


81. García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA: Large B-cell lymphoma with Hodgkin's features. Histopathology; 2005 Jul;47(1):101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma with Hodgkin's features.
  • AIMS: To describe the features of a series of nine cases of diffuse large B-cell lymphoma (DLBCL) showing morphological and immunophenotypic features that are intermediate with Hodgkin's lymphoma (HL).
  • Histopathologically, tumours showed diffuse large cell areas in a polymorphous background, with pleomorphic cytology and the common presence of Hodgkin's and Reed-Sternberg cells.
  • Immunophenotypically, tumours shared features of DLBCL and classical HL, with expression of CD30, CD15 (6/9), and a full B-cell profile including CD45RB, CD20, CD79a and OCT2.
  • CONCLUSIONS: These findings suggest that DLBCLs with HL features constitute a distinctive subgroup of aggressive lymphomas whose neoplastic growth and peculiar characteristics could be facilitated by a particular microenvironment found in the mediastinum.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Middle Aged. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Transcription Factors / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982329.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


82. Tsukahara S, Yamamoto S, Tin-Tin-Win-Shwe, Ahmed S, Kunugita N, Arashidani K, Fujimaki H: Inhalation of low-level formaldehyde increases the Bcl-2/Bax expression ratio in the hippocampus of immunologically sensitized mice. Neuroimmunomodulation; 2006;13(2):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhalation of low-level formaldehyde increases the Bcl-2/Bax expression ratio in the hippocampus of immunologically sensitized mice.
  • In the present study, we examined the effects of FA on apoptotic mechanisms regulating survival and death of cells and on N-methyl-D-aspartate (NMDA) receptors related to hippocampal functions in the mouse hippocampus.
  • METHODS: Western blot analyses were performed for Bcl-2, Bax and NMDA receptor subtypes 2A and 2B of the hippocampus taken from C3H mice exposed to 0 or 400 ppb of FA with or without ovalbumin (OVA) immunization.
  • RESULTS: The ratio of Bcl-2 to Bax expression levels significantly increased with 400-ppb FA exposure in OVA-immunized mice but not in mice without OVA immunization, although differences in each protein level were not significant among groups.
  • Active caspase- 3-immunoreactive cells were found in the hippocampus.
  • NMDA receptor type 2A and 2B expression levels of FA-exposed mice were sustained at comparative levels with those for the control mice with or without OVA immunization.
  • CONCLUSIONS: These results indicate that changes in the Bcl-2/Bax expression ratio, which occurs with low-level FA exposure and immunization and may follow enhancement of nerve growth factor production, exerts a protective effect against cell death by apoptosis.
  • [MeSH-minor] Animals. Caspase 3 / drug effects. Caspase 3 / metabolism. Cell Survival / drug effects. Cell Survival / immunology. Female. Immunization. Mice. Mice, Inbred C3H. Neurotoxins / toxicity. Ovalbumin / immunology. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptors, N-Methyl-D-Aspartate / drug effects. Receptors, N-Methyl-D-Aspartate / metabolism. Up-Regulation / drug effects. Up-Regulation / immunology. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16888403.001).
  • [ISSN] 1021-7401
  • [Journal-full-title] Neuroimmunomodulation
  • [ISO-abbreviation] Neuroimmunomodulation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / N-methyl D-aspartate receptor subtype 2A; 0 / NR2B NMDA receptor; 0 / Neurotoxins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, N-Methyl-D-Aspartate; 0 / bcl-2-Associated X Protein; 1HG84L3525 / Formaldehyde; 9006-59-1 / Ovalbumin; 9061-61-4 / Nerve Growth Factor; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


83. García JF, García JF, Maestre L, Lucas E, Sánchez-Verde L, Romero-Chala S, Piris MA, Roncador G: Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections. J Histochem Cytochem; 2006 Jan;54(1):31-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections.
  • A new anti-BCL-6 MAb (GI191E/A8) was produced by cloning full-length BCL-6 cDNA into a eukaryotic vector and delivering this into mouse epidermis using a helium gene gun.
  • A comparative study was made of the specificity and the effects of formalin fixation on immunohistochemistry quality of GI191E/A8 and two other anti-BCL-6 MAbs.
  • To evaluate its possible application to differential diagnosis of lymphomas, two tissue microarrays (89 diffuse large B-cell lymphomas and 24 B-cell chronic lymphocytic leukemia cases) were stained with GI191E/A8 and another anti-BCL-6 MAb produced by conventional means.
  • Using GI191E/A8, the detection of BCL-6 protein was significantly increased, and its specificity was independent of formalin-fixation time.
  • Using automatic quantified analysis, the correlation between the two anti-BCL-6 MAbs tested was identical in cases with overexpression or absence of BCL-6.
  • In cases with intermediate BCL-6 protein expression, detection with GI191E/A8 was more sensitive.
  • A significant association of higher BCL-6 expression and longer median overall survival times in diffuse large B-cell lymphomas was found.
  • [MeSH-minor] Animals. Cell Line, Tumor. Diagnosis, Differential. Fixatives. Formaldehyde. Humans. Immunohistochemistry. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Mice. Mice, Inbred BALB C. Palatine Tonsil / metabolism. Paraffin Embedding. Survival Analysis. Tissue Array Analysis

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046671.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Fixatives; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


84. Weng Y, Gao ZF, Liu K, Zhang WJ, Ke XY, Li M: [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese]. Zhonghua Nei Ke Za Zhi; 2005 Sep;44(9):681-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
  • OBJECTIVE: To study the correlation between clinical prognosis and clinicopathologic features, origin and cell proliferous index of diffuse large B-cell lymphoma (DLBCL) in China.
  • Immunohistochemistry stain was used to check the expression of CD(45)RO, CD(3), CD(20), CD(79)a, CD(45)RA, Ki-67, p53 and bcl-6.
  • 23 patients 38.3% died during follow-up, the longest survival period lasting 108 months.16 died in the first year after establishment of diagnosis (16/23, 69.6%).
  • Ki-67, p53, bcl-6 were expressed in some cases (48/53, 90.6%; 26/46, 56.5%; 21/41, 51.2%).
  • The expression of bcl-6 protein was somewhat related with prognosis (P = 0.0049), but the expression of p53 was not (P = 0.5948).
  • Most of the cases died in the first year after establishment of diagnosis.
  • IPI can be used to predict the clinical outcome.
  • The expression of bcl-6 protein was somewhat related with clinical prognosis, but that of p53 was not.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. China. DNA-Binding Proteins / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202261.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


85. Willenbrock K, Bräuninger A, Hansmann ML: Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol; 2007 Sep;138(6):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases.
  • Secondary lymphomas occurring in the setting of angioimmunoblastic T-cell lymphoma (AILT) are considered to be rare.
  • A previous study detected a dysregulated hypermutation process in B-cells of AILT.
  • The present study aimed at estimating the frequency of B-cell lymphomas in AILT.
  • By studying the expression of EBV and activation-induced cytidine deaminase (AID) as an indicator of hypermutating cells, we assessed whether B-cell lymphoproliferations in AILT were strictly associated with EBV and whether hypermutation might contribute to lymphomagenesis.
  • Among 161 cases of AILT, diagnosed between 1996 and 2005 at the lymph node registry, Frankfurt, Germany, 19 cases were detected that also had B-cell non-Hodgkin lymphoma (NHL) and two cases had classical Hodgkin lymphoma (HL).
  • EBV was detected in tumour cells of 7/18 NHL and both HL, suggesting that factors other than EBV contribute to lymphomagenesis.
  • AID was expressed in AILT in large cells disseminated in the tissue, implying that the process of somatic hypermutation is ongoing in AILT, although the GC architecture is disrupted.
  • This might be relevant in the development of secondary lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / virology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Cell Proliferation. Clone Cells. Cytidine Deaminase / analysis. DNA-Binding Proteins / analysis. Gene Rearrangement, B-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. RNA, Viral / analysis. Somatic Hypermutation, Immunoglobulin. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672882.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Viral; EC 3.4.24.11 / Neprilysin; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


86. Yun SJ, Lee KH, Yang DW, Lee JB, Kim SJ, Lee SC, Won YH: Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation. J Cutan Pathol; 2009 Jan;36(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation.
  • Spindle-shaped cells with elongated, twisted nuclei containing dispersed chromatin were also seen.
  • Immunohistochemical analysis showed that all of the cells were strongly positive for CD20, CD21, CD79a and CD45, while they were negative for CD3, CD5, CD10, CD23, CD35, CD43, CD45RO and CD68.
  • The spindle cells were also negative for smooth-muscle actin, desmin, S-100 and CD34.
  • They consistently expressed nuclear bcl-6, but did not express bcl-2, multiple myeloma-1 and p16.
  • We diagnosed him with primary cutaneous spindle cell B-cell lymphoma (PCSBCL) and treated him with six cycles of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) chemotherapy; his skin lesions disappeared completely.
  • Immunohistochemical profiles suggest that PCSBCL is a variant of primary cutaneous follicle center lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125734.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


87. Rohde G, Kermer P, Reed JC, Bähr M, Weishaupt JH: Neuron-specific overexpression of the co-chaperone Bcl-2-associated athanogene-1 in superoxide dismutase 1(G93A)-transgenic mice. Neuroscience; 2008 Dec 10;157(4):844-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuron-specific overexpression of the co-chaperone Bcl-2-associated athanogene-1 in superoxide dismutase 1(G93A)-transgenic mice.
  • Bcl-2-associated athanogene-1 (BAG1) binds heat-shock protein 70 (Hsp70)/Hsc70, increases intracellular chaperone activity in neurons and proved to be protective in several models for neurodegeneration.
  • Moreover, expression of mtSOD1 decreases BAG1 levels in a motoneuronal cell line.
  • [MeSH-minor] Age Factors. Amyotrophic Lateral Sclerosis / genetics. Amyotrophic Lateral Sclerosis / metabolism. Amyotrophic Lateral Sclerosis / mortality. Amyotrophic Lateral Sclerosis / pathology. Animals. Disease Models, Animal. Humans. Mice. Mice, Transgenic. Motor Activity / genetics. Phosphopyruvate Hydratase / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Spinal Cord / pathology. Survival Analysis

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955116.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2-associated athanogene 1 protein; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; EC 1.15.1.- / SOD1 G93A protein; EC 1.15.1.1 / Superoxide Dismutase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


88. Jin Y, Hu J, Wang Q, Li Z, Chen Y: Effects of Oxymatrine on the apoptosis of human esophageal carcinoma Eca109 cell line and its mechanism. J Huazhong Univ Sci Technolog Med Sci; 2008 Jun;28(3):314-6
PDF icon [Fulltext servi